Methods and compositions for assessing tissue and organ damage
By detecting the methylation pattern of cell-free DNA in blood and utilizing tissue-specific target polynucleotides combined with machine learning algorithms, the problem of insufficient sensitivity and specificity in organ damage assessment in existing technologies has been solved, achieving efficient and accurate assessment of organ damage or toxicity.
Patent Information
- Application Number
- CN202580029010.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-20
- Filing Date
- 2025-02-18
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies lack biomarkers that can accurately assess drug damage or toxicity to various organs, especially in the assessment of damage to organs such as the liver, kidneys, heart, and testes. Traditional methods lack sufficient sensitivity and specificity, and there is a lack of effective non-invasive detection methods.
This study employs a methylation pattern based on cell-free DNA. By constructing a tissue-specific or organ-specific target polynucleotide methylation status assessment method, it utilizes kits, devices, and systems to detect cell-free DNA methylation patterns in blood. Combined with machine learning algorithms for analysis, this enables the assessment of organ damage or toxicity.
This provides a highly sensitive and specific non-invasive method that can accurately assess drug damage or toxicity to various organs. It is suitable for diagnosis, prognosis, stratification, and treatment monitoring, improving the accuracy and efficiency of assessment.
Smart Images

Figure CN123125347A_ABST
Abstract
Description
[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 63 / 555,516, filed February 20, 2024, the contents of which are incorporated herein by reference in their entirety for all purposes.
[0002] REFERENCE TO ELECTRONIC SEQUENCE LISTING This application contains a sequence list that has been electronically submitted in .XML format, and is hereby incorporated in its entirety by reference. The .XML copy was created on February 17, 2025, named "4552-2000740.xml", and is 646,668 bytes in size. The sequence list contained in this .XML file is part of this specification and is hereby incorporated in its entirety by reference. Technical Field
[0003] This disclosure relates to specific compositions, kits, devices, systems, and methods, for example, for assessing the methylation status of a subject and / or assessing tissue and / or organ damage or toxicity in a subject. In a particular aspect, this document provides compositions, kits, devices, systems, and methods for assessing tissue and / or organ damage or toxicity in a subject based on the assessment of the methylation status of one or more selected tissue-specific or organ-specific target polynucleotides (e.g., one or more tissue-specific or organ-specific target genomic DNA sequences) from the subject. Background Technology
[0004] In drug development, it is necessary to assess the toxicity of candidate compounds. It is essential to consider the various effects of administered drug candidates on organs. In addition to direct examination of tissue histopathology, biomarkers representing the state of each organ are used to assess toxicity. Generally, organs-specific proteins are commonly used as biomarkers. Alternatively, indicators representing the components and functions contained within cells are sometimes used as biomarkers. In the case of the liver, the activities of the liver enzymes alanine aminotransferase and aspartate aminotransferase in the blood are widely used as indicators of liver injury. miR-122, which is primarily expressed in the liver, has been reported as a biomarker of hepatotoxicity (1, 2). For the kidneys, blood urea nitrogen and creatinine are routinely measured to detect nephrotoxicity. Kidney injury molecule-1, which is specifically expressed in kidney injury, has recently been reported as a useful biomarker (3). For the heart, cardiac troponin, which is highly expressed in the heart, is commonly used as an indicator of myocardial injury (4). Some of these biomarkers can be measured using automated clinical laboratory analyses, but many emerging biomarkers still require individual measurement via ELISA or other methods, and the methods used to measure these biomarkers may be insufficient in sensitivity and specificity due to their imprecision. Furthermore, there may be no biomarkers for detecting organ toxicity, or emerging biomarkers may not yet be clinically viable. For example, common in drug development, there are no clinically useful biomarkers for testicular toxicity. Although there are reports on hormones (5, 6) and circulating microRNAs, their clinical applicability has not been confirmed. Therefore, to develop promising and safer drugs, biomarkers that can accurately monitor their effects on various organs are needed. For this purpose, the performance of the biomarkers and the precision of the measurement methods are critical issues.
[0005] Cell-free DNA is thought to be released from cells primarily through apoptosis and necrosis, and possibly also through active secretion. Outside of the bloodstream, cell-free DNA has been detected in various bodily fluids, including urine, cerebrospinal fluid, pleural fluid, and saliva (7). Bronkhorst et al. reported that the presence of cell-free DNA may be a result of actively secreted DNA, perhaps related to protein complexes (8). Exercise has also been reported to increase blood DNA levels. Enhanced cardiopulmonary function during exercise may lead to the accumulation of cell-free DNA through the release of stress hormones that have increased at intensities below the anaerobic threshold (9). High cell-free DNA concentrations are a predictor of short-term mortality following severe traumatic brain injury (10). The proportion of donor DNA naturally increases one day after transplantation (since organ transplantation is essentially a genome transplant), and these levels decline exponentially within a week if the organ is received (11). Therefore, cell-free DNA in the blood may be an indicator that cells have broken down somewhere in the body.
[0006] Cell-free DNA contains a variety of information. Various genetic and epigenetic alterations, such as point mutations, copy number changes, rearrangements, and methylation changes, can be found in cell-free DNA (7). Cell-free DNA is now widely used in cancer diagnosis and prenatal diagnosis of fetuses. Its usefulness in disease status assessment has been demonstrated. Although NGS of tumor tissue is generally preferred, tissue biopsies are often unavailable or insufficient in quantity or quality, so the use of circulating tumor DNA (ctDNA) analysis in blood is the only available option. Liquid biopsy allows for rapid and simple multi-timepoint serial analysis, which can help guide treatment decisions by identifying the presence of mutations and other genetic alterations, thereby predicting resistance or response to next-line therapies. Therapeutic interventions may also lead to changes in ctDNA levels in the blood (12). Non-invasive prenatal testing (NIPT) has been used to determine fetal sex, fetal rhesus monkey D (RhD) genotyping, and to identify some pregnancy-related conditions such as preeclampsia, aneuploidy, and paternally inherited monogenic diseases (13).
[0007] Therefore, there is a need for improved compositions, kits, devices, systems, and methods to assess tissue and / or organ damage or toxicity in subjects. This disclosure addresses this need and other related needs. Summary of the Invention
[0008] The present invention is not intended to limit the scope of the claimed subject matter. Other features, details, utility, and advantages of the claimed subject matter will be apparent from the detailed description (including the figures and those aspects disclosed in the appended claims).
[0009] A method for detecting trace amounts of cancer-derived cell-free DNA in the blood has been developed (14) and is already in clinical use. Because this method is based on specific DNA methylation patterns in cells across various organs, we chose it for this study to explore the feasibility and effectiveness of using cell-free DNA as a biomarker to identify damaged tissues in animal toxicity studies. First, we demonstrated the possibility of creating a DNA methylation database for each organ in rats and identified liver-specific methylation patterns. Rats were administered the typical hepatotoxic agent thioacetamide (TAA), and cell-free DNA at the onset of hepatotoxicity was analyzed to determine the extent to which liver-specific methylation patterns were included. We also compared numerical indicators of liver-specific methylation patterns with existing liver biomarkers such as AST and ALT to determine their detection sensitivity.
[0010] In one respect, this article provides a set of isolated polynucleotides comprising, consisting of, or substantially consisting of one or more isolated tissue-specific or organ-specific target polynucleotides or sequences complementary to or substantially complementary to them.
[0011] In another aspect, a kit, device, system, or article is configured to assess the methylation status of one or more tissue-specific or organ-specific target polynucleotides. In some embodiments, the kit, device, system, or article of the present invention is configured to assess tissue and / or organ damage or toxicity in a subject.
[0012] In another aspect, this document provides an in vitro method for classifying samples, the method comprising: a) in vitro assessing the methylation status of one or more tissue-specific or organ-specific target polynucleotides of a subject in a sample, the sample comprising cellular free target polynucleotides from the subject; and b) classifying the sample into a category based on the methylation status of the one or more tissue-specific or organ-specific target polynucleotides in the sample obtained in a); in some embodiments, the method of the present invention is used to assess tissue and / or organ damage or toxicity in a subject. In some embodiments, the method of the present invention is used for diagnosing, prognosticating, stratifying, assessing risk, or monitoring treatment for tissue and / or organ damage or toxicity in a subject. Attached Figure Description
[0013] Figure 1 An exemplary support vector machine analysis is demonstrated. Figure 1 Image taken from Wikipedia: https: / / en.wikipedia.org / wiki / Support_vector_machine This does not represent any DNA methylation status analysis or cancer assessment.
[0014] Figure 2 Steps for constructing a single-stranded polynucleotide library and performing sequencing analysis using the library are illustrated according to one aspect of this disclosure.
[0015] Figure 3 A construct comprising a target molecule for sequencing is shown according to one aspect of this disclosure.
[0016] Figure 4A-24C illustrates exemplary analyses of cfDNA and other liver biomarkers. The horizontal axis shows measurements of AST and ALT, and the vertical axis shows liver methylation scores. (A) Detection of liver injury using cfDNA biomarkers. Liver methylation scores for each cfDNA biomarker were calculated from plasma samples and liver genomic DNA obtained from rats. (B) Comparison of ALT / AST with liver methylation scores. A scatter plot of ALT / AST values and liver methylation scores was plotted. (C) Spike-in simulation. Computer simulations were performed to simulate lower levels of hepatotoxicity. Mixed sequencing reads from plasma TAA 9 hours and untreated plasma were used. 10%:90% mixtures could be reliably detected.
[0017] Figure 5 An exemplary detection of drug-induced testicular injury in rats is presented. (A) Detection of testicular injury using cfDNA biomarkers. A testicular methylation score for cfDNA in plasma samples obtained from drug-treated rats was calculated. The horizontal axis represents the number of days of drug treatment prior to blood collection, the vertical axis represents the testicular methylation score, and the legend indicates the drug dosage. (B) Comparison of histopathological severity score with testicular methylation score. A scatter plot of histopathological score relative to testicular methylation score obtained from testicular biopsy was plotted. The horizontal axis represents the histopathological score, and the vertical axis represents the testicular score.
[0018] Figure 6 An example of generating a rat tissue-specific methylation database is shown. Methylation haplotype indices from samples representing nine tissue types (colon, gastrocnemius, heart, kidney, liver, lung, small intestine, stomach, and testis) were clustered using hierarchical clustering. Heatmap colors represent the correlation coefficients between each sample.
[0019] Figure 7 The Python code used in Example 1 is shown.
[0020] Figure 8 The Python code used in Example 2 is shown.
[0021] Figure 9 The Python code used in Example 3 is shown. Detailed Implementation
[0022] Numerous specific details are set forth in the following description in order to provide a thorough understanding of this disclosure. These details are provided for the purposes of embodiments, and the claimed subject matter may be practiced according to the claims without some or all of these specific details. It should be understood that other implementations may be used and structural changes may be made without departing from the scope of the claimed subject matter. It should be understood that the various features and functions described in one or more individual embodiments are not limited to being applicable only to the specific embodiments in which they are described. Rather, whether or not these implementations are described, and whether or not these features are presented as part of the described implementations, they may be applied individually or in some combination to one or more other implementations of this disclosure. For clarity, technical materials known in the art related to the claimed subject matter have not been described in detail so as not to unnecessarily obscure the claimed subject matter.
[0023] All publications mentioned in this application, including patent documents, scientific papers, and databases, are incorporated herein by reference in their entirety for all purposes, to the same extent that each individual publication is incorporated separately by reference. Reference to these publications or documents is not intended to acknowledge that any of them are relevant prior art, nor is it intended to acknowledge the content or date of such publications or documents.
[0024] All headings are for the reader's convenience and should not be used to limit the meaning of the text following them, unless otherwise specified.
[0025] Unless otherwise stated, the practices provided will be implemented using conventional techniques and descriptions of organic chemistry, polymer technology, molecular biology (including recombinant technologies), cell biology, biochemistry, and sequencing technologies within the skill level of those skilled in the art. Such conventional techniques include peptide and protein synthesis and modification, polynucleotide synthesis and modification, polymer array synthesis, polynucleotide hybridization and ligation, hybridization detection, and nucleotide sequencing. Specific descriptions of suitable techniques can be found in the embodiments described herein. However, other equivalent conventional procedures may of course be used. Such conventional techniques and descriptions can be found in standard laboratory manuals, such as Green et al., ed., *Genome Analysis: A Laboratory Manual Series*. Genome Analysis: A Laboratory Manual Series ) (Volumes I-IV) (1999); Edited by Weiner, Gabriel, and Stephens, *Gene Variation: A Laboratory Manual* Genetic Variation: A Laboratory Manual ) (2007); Dieffenbach, Dveksler (eds.), PCR Primers: A Laboratory Manual ( PCR Primer:A Laboratory Manual (2003); Bowtell and Sambrook, DNA Microarrays: A Handbook of Molecular Cloning ( DNA Microarrays: A Molecular Cloning Manual ) (2003); Mount, Bioinformatics: Sequence and Genome Analysis ( Bioinformatics: Sequence and Genome Analysis (2004); Sambrook and Russell, Molecular Cloning Concentration Protocols: A Laboratory Manual (2004) Condensed Protocols from Molecular Cloning: A Laboratory Manual (2006); and Sambrook and Russell, Molecular Cloning: A Laboratory Manual (2006); Molecular Cloning: A Laboratory Manual ) (2002) (both from Cold Spring Harbor Laboratory Press); Ausubel et al., *Experimental Guide to Contemporary Molecular Biology* (2002) Current Protocols in Molecular Biology ) (1987); T. Brown, ed., *Basic Molecular Biology* (1987); Essential Molecular Biology ) (1991), IRL Press; Edited by Goeddel, Gene Expression Technology ( Gene Expression Technology ) (1991), Academic Press; A. Bothwell et al., eds., Cloning and Analysis Methods of Eukaryotic Genes ( Methods for Cloning and Analysis of Eukaryotic Genes ) (1990), Bartlett Publ.; M. Kriegler, Gene Transfer and Expression ( Gene Transfer and Expression ) (1990), Stockton Press; edited by R. Wu et al., *Recombinant DNA Methods ( Recombinant DNA Methodology ) (1989), Academic Press; M. McPherson et al., PCR: A Practical Method ( PCR: A Practical Approach ) (1991), Oxford University Press IRL; Stryer, Biochemistry ( Biochemistry (4th Edition) (1995), W.H. Freeman, NY; Gait, "Oligonucleotide Synthesis: Practical Methods" (4th Edition) (1995), Oligonucleotide Synthesis:A Practical Approach, (2002), IRL Press, London; Nelson and Cox, Lehninger, Principles of Biochemistry ( Principles of Biochemistry ), (2000), 3rd edition, WH Freeman Pub., New York, NY; Berg et al., Biochemistry ( Biochemistry References are cited in their entirety for all purposes and are incorporated herein by reference. (2002), 5th edition, WH Freeman, New York, NY.
[0026] A. Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. If any definition set forth in this section conflicts with or is inconsistent with definitions described in patents, applications, publications, or other publications incorporated herein by reference, the definitions set forth in this section shall prevail over those incorporated herein by reference.
[0027] As used herein, “a / an” means “at least one” or “one or more”. As used herein, unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the” include the plural designation.
[0028] Throughout this disclosure, all aspects of the claimed subject matter are presented in scope. It should be understood that this scope-based description is merely for convenience and brevity and should not be construed as a rigid limitation on the scope of the claimed subject matter. Therefore, the description of scope should be considered as having specifically disclosed all possible sub-scopes and individual numerical values within those scopes. For example, in the case of providing a range of values, it should be understood that every intermediate value between the upper and lower limits of the stated range, as well as any other specified value or intermediate value within the stated range, is encompassed within the claimed subject matter. The upper and lower limits of these smaller ranges may be independently included within the smaller ranges and are also encompassed within the claimed subject matter, subject to any particular exclusion within the stated range. In the case of including one or both of the stated limits at a given scope, the scope excluding any one or both of the included limits is also included within the claimed subject matter. This applies regardless of the breadth of the scope.
[0029] The use of “about” in this document includes (and describes) variations of the value or parameter itself. For example, a description referring to “about X” includes a description of “X”. Additionally, the use of “about” before any series of numbers includes “about” each number listed in that series. For example, a description referring to “about X, Y, or Z” is intended to describe “about X, about Y, or about Z”. Unless the context clearly indicates otherwise, as used herein, the term “average” means the mean or median, or any value used to approximate the mean or median.
[0030] As used herein, “subject” means an organism or part or component of an organism to which the provided compositions, methods, kits, devices, and systems may be administered or applied. For example, a subject may be a mammal or a cell, tissue, organ, or part of a mammal. As used herein, “mammal” means any species of mammal, preferably human (including humans, human subjects, or human patients). Subjects and mammals include, but are not limited to, farm animals, livestock, pets, primates, horses, dogs, cats, and rodents such as mice and rats.
[0031] As used herein, the term "sample" means any substance that may contain the target molecules to be analyzed, including biological samples. As used herein, "biological sample" can mean any macromolecular and biomolecular sample obtained from a living or viral (or prion) source or other source, and includes any cell type or tissue of a subject from which nucleic acids, proteins, and / or other macromolecules may be obtained. Biological samples can be samples obtained directly from biological sources or processed samples. For example, amplified isolated nucleic acids constitute a biological sample. Biological samples include, but are not limited to, bodily fluids (such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, sweat, semen, feces, sputum, tears, mucus, amniotic fluid, or the like), exudates, bone marrow samples, ascites, pelvic lavage fluid, pleural fluid, cerebrospinal fluid, lymph, eye discharge, extracts from nasal, throat, or genital swabs, cell suspensions from digestive tissues or extracts from fecal material, and tissue and organ samples from humans, animals (e.g., non-human mammals) and plants, and processed samples derived therefrom.
[0032] The terms “polynucleotide,” “oligonucleotide,” “nucleic acid,” and “nucleic acid molecule” are used interchangeably herein and refer to a polymeric form of nucleotides of any length, including ribonucleotides, deoxyribonucleotides, and their analogues or mixtures. The terms include triple-stranded, double-stranded, and single-stranded deoxyribonucleic acid (“DNA”) and triple-stranded, double-stranded, and single-stranded ribonucleic acid (“RNA”). The terms also include modified polynucleotides (e.g., through alkylation and / or capping) and unmodified forms of polynucleotides. More specifically, the terms “polynucleotide,” “oligonucleotide,” “nucleic acid,” and “nucleic acid molecule” include polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose) (including tRNA, rRNA, hRNA, and mRNA, whether spliced or unspliced), any other type of polynucleotide as an N- or C-glycoside of a purine or pyrimidine base, other polymers containing a non-nucleotide backbone (e.g., polyamides (e.g., peptide nucleic acids (“PNA”)) and polymorpholinopolymers (commercially available from Anti-Virals, Inc., Corvallis, OR, through Neugene), and other synthetic sequence-specific nucleic acid polymers (provided that the polymer contains nucleobases in a configuration that allows base pairing and base stacking, as found in DNA and RNA). Therefore, these terms include, for example, 3'-deoxy-2',5'-DNA, oligodeoxyribonucleotides N3' to P5' aminophosphates, 2'-O-alkyl-substituted RNA, hybrids between DNA and RNA or between PNA and DNA or RNA, and also include modifications of known types, such as labeling, alkylation, "capping", substitution of one or more nucleotides in a nucleotide with an analogue, internucleotide modifications (e.g., having uncharged bonds (e.g., methylphosphonates, phosphate triesters, aminophosphates, carbamates, etc.)), having negatively charged bonds (e.g., thiophosphates, etc.). Nucleic acids (such as dithiophosphates) and those with positively charged bonds (e.g., aminoalkylaminophosphates, aminoalkyltriphosphates), those containing side group moieties, such as proteins (including enzymes (e.g., nucleases), toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalating agents (e.g., acridine, psoralen, etc.), those containing chelating agents (e.g., chelating agents of metals, radioactive metals, boron, metal oxides, etc.), those containing alkylating agents, those with modified bonds (e.g., α-anomeric nucleic acids, etc.), and unmodified forms of polynucleotides or oligonucleotides). Nucleic acids will generally contain phosphodiester bonds, but in some cases, they may include nucleic acid analogs with alternative backbones, such as phosphoramide, dithiophosphate, or methylphosphamide bonds; or peptide nucleic acid backbones and bonds.Other analog nucleic acids include those with a bicyclic structure, including locked nucleic acids, positively charged backbones, nonionic backbones, and nonribose backbones. The ribose-phosphate backbone can be modified to increase molecular stability; for example, PNA:DNA hybrids can exhibit higher stability in some environments. The terms "polynucleotide," "oligonucleotide," "nucleic acid," and "nucleic acid molecule" can include any suitable length, such as at least 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, or more nucleotides.
[0033] It should be understood that, as used herein, the terms "nucleoside" and "nucleotide" include moieties containing not only known purine and pyrimidine bases but also other modified heterocyclic bases. Such modifications include methylated purines or pyrimidines, acylated purines or pyrimidines, or other heterocyclic compounds. Modified nucleosides or nucleotides may also include modifications to the sugar moiety, for example, where one or more hydroxyl groups are replaced by halogens, aliphatic groups, or functionalized to ethers, amines, etc. The term "nucleotide unit" is intended to encompass both nucleosides and nucleotides.
[0034] The terms "complementary" and "substantially complementary" encompass hybridization or base pairing or double-strand formation between nucleotides or nucleic acids, for example, between the two strands of a double-stranded DNA molecule, or between an oligonucleotide primer and a primer binding site on a single-stranded nucleic acid. Complementary nucleotides are typically A and T (or A and U), or C and G. Two single-stranded RNA or DNA molecules are said to be substantially complementary when the nucleotides of one strand are optimally aligned and compared and have appropriate nucleotide insertions or deletions, pairing with at least about 80%, typically at least about 90% to about 95%, and even about 98% to about 100% of the other strand. In another aspect, two complementary sequences of nucleotides are capable of hybridization, preferably with less than 25% mismatch between opposing nucleotides, more preferably less than 15% mismatch, even more preferably less than 5% mismatch, and most preferably no mismatch. Preferably, the two molecules will hybridize under highly stringent conditions.
[0035] As used herein, for a reference sequence, the inverse complementary sequence is the sequence that is complementary to the reference sequence in reverse order. For example, for 5'-ATCG-3', the complementary sequence is 3'-TAGC-5', and the inverse complementary sequence is 5'-CGAT-3'.
[0036] As used herein, “hybridization” can refer to the process by which two single-stranded polynucleotides non-covalently combine to form a stable double-stranded polynucleotide. In one aspect, the resulting double-stranded polynucleotide can be a “hybrid” or a “double strand.” “Hybridization conditions” typically include salt concentrations of approximately less than 1 M, typically less than about 500 mM, and possibly less than about 200 mM. “Hybridization buffers” include buffered salt solutions, such as 5% SSPE, or other such buffers known in the art. Hybridization temperatures can be as low as 5 °C, but are typically greater than 22 °C, and more typically greater than about 30 °C, and usually exceed 37 °C. Hybridization is typically performed under stringent conditions, i.e., conditions under which the sequence hybridizes with its target sequence but not with other non-complementary sequences. Stringent conditions are sequence-dependent and vary under different conditions. For example, for specific hybridization, longer fragments may require higher hybridization temperatures than shorter fragments. Because other factors can affect the stringency of hybridization, including the base composition and length of the complementary strand, the presence of organic solvents, and the degree of base mismatch, the combination of parameters is more important than any single parameter as an absolute measure. Typically, stringent conditions are chosen to be more stringent than the T values of a specific sequence at defined ionic strengths and pH. m Approximately 5°C lower. Chain-breaking temperature T m This can be the temperature at which half of a double-stranded nucleic acid molecule population dissociates into single strands. It is used to calculate the T0 of nucleic acids. m Several equations are well known in the art. As shown in standard references, when nucleic acids are in an aqueous solution of 1 M NaCl, T m A simple estimate of the value can be obtained through equation T. m =81.5 + 0.41 (% G + C) calculation (see, for example, Anderson, MLM and Young, BD 1985, Quantitative filter hybridization. in Nucleic acid hybridization: a practical approach, 73-111. BDHames and SJ Higgins (eds.). IRL Press Limited, Oxford.). Other references (e.g., Allai and SantaLucia, Jr., Biochemistry, 36:10581-94 (1997)) include alternative methods of calculation that take into account structure and environment as well as sequence characteristics in T m In the calculation.
[0037] Typically, the stability of hybrids is a function of ion concentration and temperature. Hybridization reactions are usually carried out under less stringent conditions, followed by washings of varying but higher stringency. Exemplary stringent conditions include a salt concentration of at least 0.01 M to no more than 1 M sodium ion (or other salt) at a pH of about 7.0 to about 8.3 and a temperature of at least 25°C. For example, although suitable temperatures depend on the length of the hybridized region and / or GC content, conditions of 5 × SSPE (750 mM NaCl, 50 mM sodium phosphate, 5 mM EDTA, pH 7.4) and a temperature of about 30°C are suitable for allele-specific hybridization. In one respect, the “hybridization stringency” of a percentage mismatch can be determined as follows: 1) High stringency: 0.1 × SSPE, 0.1% SDS, 65 C; 2) Medium strictness: 0.2 × SSPE, 0.1% SDS, 50 C (also known as mild strictness); and 3) low strictness: 1.0 × SSPE, 0.1% SDS, 50 C. It should be understood that equivalent stringency can be achieved using alternative buffers, salts, and temperatures. For example, moderately stringent hybridization can refer to conditions that allow nucleic acid molecules (such as probes) to bind to complementary nucleic acid molecules. The hybridized nucleic acid molecules typically have at least 60% identity, including at least any of, for example, 70%, 75%, 80%, 85%, 90%, or 95% identity. Moderately stringent conditions can be equivalent to hybridization at 42°C in 50% formamide, 5× Denhardt's solution, 5× SSPE, and 0.2% SDS, followed by washing at 42°C in 0.2× SSPE and 0.2% SDS. High stringency conditions can be provided, for example, hybridization at 42°C in 50% formamide, 5× Denhardt's solution, 5× SSPE, and 0.2% SDS, followed by washing at 65°C in 0.1× SSPE and 0.1% SDS. Low-toughness hybridization can refer to conditions equivalent to hybridization at 22°C in 10% formamide, 5× Dunhardt solution, 6× SSPE, and 0.2% SDS, followed by washing at 37°C in 1× SSPE and 0.2% SDS. The Dunhardt solution contains 1% sucrose, 1% polyvinylpyrrolidone, and 1% bovine serum albumin (BSA). 20× SSPE (sodium chloride, sodium phosphate, EDTA) contains 3M sodium chloride, 0.2M sodium phosphate, and 0.025M EDTA. Other suitable medium-toughness and high-toughness hybridization buffers and conditions are well known to those skilled in the art and are described below: for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*.A Laboratory Manual ), 2nd edition, Cold Spring Harbor Press, Plainview, NY (1989); and Ausubel et al., Short Protocols in Molecular Biology, 4th edition, John Wiley & Sons, (1999).
[0038] Alternatively, substantial complementarity exists when the RNA or DNA strand hybridizes with its complement under selective hybridization conditions. Typically, selective hybridization occurs when there is at least about 65% complementarity, preferably at least about 75%, and more preferably at least about 90% complementarity, within an extension of at least 14 to 25 nucleotides. See M. Kanehisa, Nucleic Acid Research, 12:203 (1984).
[0039] The “primers” used in this article can be natural or synthetic oligonucleotides that act as initiation sites for nucleic acid synthesis when forming a double helix with a polynucleotide template and extend from their 3' end along the template, thus forming an extended double helix. The sequence of the nucleotides added during the extension process is determined by the sequence of the template polynucleotide. Primers are typically extended by polymerases such as DNA polymerase.
[0040] "Lie-off" can refer to the formation of a covalent bond or linkage between the ends of two or more nucleic acids (e.g., oligonucleotides and / or polynucleotides) in a template-driven reaction. The nature of the bond or linkage can vary widely, and ligation can occur enzymatically. As used herein, ligation is typically enzymatic to form a phosphodiester bond between the 5' carbon-terminal nucleotide of one oligonucleotide and the 3' carbon of another nucleotide.
[0041] As used herein, “amplification” generally refers to the process of producing multiple copies of the desired sequence. “Multiple copies” means at least two copies. “Copy” does not necessarily mean complete sequence complementarity or sequence identity with the template sequence. For example, copies may include nucleotide analogues such as deoxyinosine, intentional sequence alterations (such as sequence alterations introduced by primers containing sequences that hybridize to but are not complementary to the template), and / or sequence errors that occur during amplification.
[0042] Terms such as "sequencing" include determining information related to the nucleotide base sequence of a nucleic acid. This information can include the identification or determination of partial and complete sequence information of the nucleic acid. Sequence information can be determined with varying degrees of statistical reliability or confidence. In one aspect, the term includes determining the identity and sequence of multiple consecutive nucleotides in a nucleic acid.
[0043] The terms “sequencing,” “high-throughput sequencing,” or “next-generation sequencing” refer to sequencing that uses methods to determine many (typically thousands to billions) nucleic acid sequences in an essentially parallel manner, where DNA templates are not prepared one at a time for sequencing, but in a batch process, and where many sequences are preferably read out in parallel, or alternatively, an ultra-high-throughput serial process that can itself be parallelized. Such methods include, but are not limited to, pyrosequencing (e.g., commercialized by 454 Life Sciences, Inc., Branford, CT); sequencing-by-ligation (e.g., commercialized in SOLiD™ technology by LifeTechnology, Inc., Carlsbad, CA); sequencing-by-synthesis using modified nucleotides (e.g., TruSeq™ and HiSeq™ technologies by Illumina, Inc., San Diego, CA; HeliScope™ by Helicos Biosciences Corporation, Cambridge, MA; and PacBio RS by Pacific Biosciences of California, Inc., Menlo Park, CA); and sequencing via ion detection technologies (e.g., Ion detection by Life Technologies, Carlsbad, CA). Torrent™ technology; sequencing of DNA nanospheres (Complete Genomics, Inc., Mountain View, CA); nanopore-based sequencing technologies (e.g., developed by Oxford Nanopore Technologies, LTD, Oxford, UK) and similar highly parallel sequencing methods.
[0044] “SNP” or “single nucleotide polymorphism” can include genetic variation between individuals; for example, a variable single nitrogenous base position in an organism’s DNA. SNPs are present throughout the genome; many genetic variations between individuals are due to variations at SNP loci, and such genetic variations often lead to phenotypic variations between individuals. The SNPs and their corresponding alleles used in this disclosure can be derived from any number of sources, such as public databases (UC Santa Cruz Human Genome Browser Gateway (genome.ucsc.edu / cgi-bin / hgGateway) or NCBI dbSNP website (ncbi.nlm.nih.gov / SNP / ), or can be determined experimentally, such as U.S. Patent No. 6,969,589; and entitled “Human Genomic Polymorphism”. The use of SNPs is described in U.S. Publication No. 2006 / 0188875, “Polymorphisms”. While the use of SNPs is described in some embodiments presented herein, it should be understood that other biallelic or polyelelic genetic markers may also be used. A biallelic genetic marker is a marker having two polymorphic forms or alleles. As stated above, for a trait-associated biallelic genetic marker, the allele that is more abundant in the genetic makeup of the case group compared to the control group is called the “associated allele,” and the other allele may be called the “unassociated allele.” Thus, for each biallelic polymorphism associated with a given trait (e.g., disease or drug response), there exists a corresponding associated allele. Other biallelic polymorphisms that may be used with the methods presented herein include, but are not limited to, polynucleotide alterations, insertions, deletions, and translocations.
[0045] To further understand, the DNA mentioned in this article can include genomic DNA, mitochondrial DNA, free DNA, and / or DNA derivatives, such as amplicones, RNA transcripts, cDNA, and DNA analogs. Polymorphic loci screened in association studies can be in a diploid or haploid state, and ideally, should originate from sites across the entire genome. Sequencing technologies can be used for SNP sequencing, such as the BeadArray platform (GOLDENGATE). TM (Detection) (Illumina, Inc., San Diego, CA) (See Fan et al., Cold Seed Quantitative Biology Symposium) Cold Spring Symp. Quant. Biol. )》, 68:69-78 (2003)).
[0046] In some implementations, the term "methylation state" or "methylation status" refers to the presence or absence of 5-methylcytosine ("5-mC" or "5-mCyt") at one or more CpG dinucleotides within a DNA sequence. The methylation status at one or more specific CpG methylation sites (each with two CpG dinucleotide sequences) within a DNA sequence includes "unmethylated," "fully methylated," and "hemimethylated." The term "hemimethylation" or "hemimethylation" refers to the methylation state of double-stranded DNA, where only one strand is methylated. The term "hypermethylation" refers to the average methylation state corresponding to an increase in the amount of 5-mCyt at one or more CpG dinucleotides within the DNA sequence of a test DNA sample compared to the amount of 5-mCyt found at the corresponding CpG dinucleotide in a normal control DNA sample. The term "hypomethylation" refers to the average methylation state in which the amount of 5-mCyt at one or more CpG dinucleotides is reduced compared to the amount of 5-mCyt found at the corresponding CpG dinucleotide in a normal control DNA sample.
[0047] "Multiplex" or "multiplex assay" in this document may refer to assays or other analytical methods in which the presence, quantity, and / or methylation status (or methylation state) of multiple targets (e.g., multiple nucleic acid sequences) can be determined simultaneously using more than one biomarker, each of which has at least one distinct detection feature, such as fluorescence features (e.g., excitation wavelength, emission wavelength, emission intensity, FWHM (full width at half maximum) or fluorescence lifetime) or unique nucleic acid or protein sequence features.
[0048] As used herein, “disease or symptom” refers to a pathological condition in an organism caused by, for example, infection or genetic defect, and is characterized by identifiable symptoms.
[0049] B. Groups of isolated polynucleotides and related compositions On the one hand, this article provides a set of isolated polynucleotides, which include, consist of, or consist essentially of one or more isolated tissue-specific or organ-specific target polynucleotides or sequences that are complementary to or substantially complementary to them.
[0050] In some embodiments, the group of the present invention may include one or more isolated liver-specific target polynucleotides or sequences complementary to or substantially complementary to them. For example, one, more, or each isolated tissue-specific or organ-specific target polynucleotide in the group of the present invention may: a) be located in one or more liver-specific genes as listed in Table 1; or b) may include, substantially consist of, or consist of one or more sequences shown in SEQ ID NO: 246-730 or sequences complementary to or substantially complementary to them.
[0051] In some embodiments, the group of the present invention may include one or more isolated testis-specific target polynucleotides or sequences complementary or substantially complementary to them. For example, one, more, or each isolated tissue-specific or organ-specific target polynucleotide in the group of the present invention: a) may be located in genes selected from the group consisting of: B3galt1, Cacng5, Ccdc162, Cdc23, Cdca2, Ceacam5, Cnot4, Crybg1, Ddr1, Dpysl4, Enc1, Fam69b, Hs6st3, Ins1, Maml2, Midn, Obox5, Pax7, Pdlim4, Rtn4ip1, Siglec15, Slc16a3, Slc22a4, Smim23, Snx33, Syndig1, Tagln, Tcf3, Trpc7 and Ttc8 b) may be located in one or more testis-specific genes listed in Table 1; or c) may include, consist of, or consist of one or more sequences shown in SEQ ID NO: 1-245 or sequences complementary to or substantially complementary to them.
[0052] The group of the present invention may include any suitable number of the above-described isolated polynucleotides, constitute or substantially constitute thereof. For example, the group of the present invention may include, constitute or substantially constitute at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000 or more isolated tissue-specific or organ-specific target polynucleotides, for example, isolated tissue-specific or organ-specific target polynucleotides of one or more tissues or organs of the whole genome of a subject, or sequences complementary or substantially complementary thereto.
[0053] The isolated polynucleotides in the group of the present invention can be any suitable type of polynucleotide. For example, the isolated tissue-specific or organ-specific target polynucleotides in the group of the present invention are DNA molecules, RNA molecules, or combinations thereof.
[0054] Isolated polynucleotides can be immobilized on a substrate. Isolated polynucleotides can be immobilized on any suitable substrate. For example, the substrate can include a solid surface, a porous surface, or a combination thereof. In some embodiments, the substrate can be part of beads, tubes, microtiter plates, membranes, gels, or glass slides. In other embodiments, the isolated polynucleotide molecules can be spatially separated from each other on the substrate so that each isolated polynucleotide molecule can be evaluated or analyzed individually.
[0055] It also provides reagent kits, devices, systems or articles that include any of the above groups.
[0056] The kits, devices, systems, or articles of the present invention can be configured for any suitable use or purpose. For example, the kits, devices, systems, or articles of the present invention can be configured to assess the methylation status of one or more tissue-specific or organ-specific target polynucleotides or sequences complementary or substantially complementary thereto in vitro, for example, to assess the methylation status of the one or more tissue-specific or organ-specific target polynucleotides or sequences complementary or substantially complementary thereto in one or more samples, said one or more samples comprising cell-free target polynucleotides from a subject. In some embodiments, the kits, devices, systems, or articles of the present invention can be configured to evaluate at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, or more isolated tissue-specific or organ-specific target polynucleotides, such as isolated tissue-specific or organ-specific target polynucleotides from the whole genome of a subject, or sequences complementary to or substantially complementary to them. In other embodiments, the isolated polynucleotides in the kits, devices, systems, or articles of the present invention can be configured as control polynucleotides.
[0057] The isolated polynucleotides in the kits, devices, systems, or articles of the present invention can have any suitable concentration level. For example, the isolated polynucleotides can have a concentration level of about 1 femtomolar to about 100 millimoles, such as about 1 femtomolar (fM), 10 fM, 100 fM, 1 picomolar (pM), 10 pM, 100 pM, 1 nanomolar (nM), 10 nM, 100 nM, 1 micromolar (µM), 10 µM, 100 µM, 1 millimole (mM), 10 mM, 100 mM, or subranges thereof.
[0058] The kits, devices, systems, or articles of the present invention can be configured for any suitable use or purpose. For example, the kits, devices, systems, or articles of the present invention can be configured to assess tissue and / or organ damage or toxicity in a subject.
[0059] The one or more tissue-specific or organ-specific target polynucleotides may comprise, consist of, or substantially consist of at least two consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, wherein the tissue-specific or organ-specific target gene encodes RNA or polypeptide specific to the subject's tissue or organ. In some embodiments, the one or more tissue-specific or organ-specific target polynucleotides may comprise, consist of, or substantially consist of at least two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, four hundred, fifty, sixty, seventy, eighty, ninety, one hundred, twenty hundred, thirty hundred, four hundred, fifty hundred, six hundred, seven hundred, eight hundred, nine hundred, one thousand, or more consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, wherein the tissue-specific or organ-specific target gene encodes RNA or polypeptide specific to the subject's tissue or organ.
[0060] In some embodiments, the tissue-specific or organ-specific target genes may be selectively or primarily expressed and / or translated in multiple tissues or organs of the subject. For example, tissue-specific or organ-specific target genes may be selectively or primarily expressed and / or translated in 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more tissues or organs of the subject. In some embodiments, the tissue-specific or organ-specific target genes are expressed and / or translated only in a single tissue or organ of the subject.
[0061] In some embodiments, the one or more tissue-specific or organ-specific target genes of the subject encode RNA that is specific to the subject's tissue or organ. In some embodiments, the one or more tissue-specific or organ-specific target genes of the subject encode polypeptides that are specific to the subject's tissue or organ.
[0062] In some embodiments, the one or more tissue-specific or organ-specific target polynucleotides / genes are listed in Table 1 below, or are located in a subgroup of the tissue-specific or organ-specific target polynucleotides / genes listed in Table 1. For example, the tissue-specific or organ-specific target polynucleotides / genes may be a single, multiple, or all of the tissue-specific or organ-specific target polynucleotides / genes of a specific tissue or organ or a selective group of tissues or organs listed in Table 1.
[0063] C. Kits, systems, and related compositions for evaluating methylation On the other hand, kits, devices, systems, or articles are provided that include reagents for assessing the methylation status of one or more tissue-specific or organ-specific target polynucleotides, or sequences complementary to or substantially complementary to them. In some embodiments, the kits, devices, systems, or articles of the present invention are configured to assess in vitro the methylation status of one or more isolated tissue-specific or organ-specific target polynucleotides from one or more samples comprising cell-free target polynucleotides, such as one or more blood or plasma samples obtained from one or more subjects.
[0064] The kits, devices, systems, or articles of the present invention may include reagents for assessing the methylation status of any suitable number of tissue-specific or organ-specific target polynucleotides. For example, the kits, devices, systems, or articles of the present invention may include reagents for assessing the methylation status of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, or more tissue-specific or organ-specific target polynucleotides, for example, tissue-specific or organ-specific target polynucleotides of one or more tissues or organs of a subject’s whole genome, or sequences complementary to or substantially complementary to them. In some embodiments, the kits, devices, systems, or articles of the present invention may include reagents for evaluating the methylation status of at least one, two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, fourty, fivety, sixty, seventy, eighty, ninety, ten, twenty ... In some embodiments, the kits, devices, systems, or articles of the present invention may include reagents for evaluating the methylation status of at least one, two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, fourty, fivety, sixty, seventy, eighty, ninety, ten, twenty, thirty, eighty, ninety, ten, eighty, ninety, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, teny, or teny, or more tissue-specific or organ-specific target polynucleotides located in one or more genes of one or more organs listed in Table 1 below.
[0065] Table 1. Exemplary tissue-specific or organ-specific target polynucleotides / genes The kits, devices, systems, or articles of the present invention may include any suitable reagent for assessing the methylation status of tissue-specific or organ-specific target polynucleotides. For example, the reagent may include, consist substantially of, or be composed of probes or primers configured to hybridize with each of the tissue-specific or organ-specific target polynucleotides whose methylation status is to be assessed. In some embodiments, the reagent includes, consists substantially of, or is composed of a single probe or primer configured to hybridize with each of the tissue-specific or organ-specific target polynucleotides whose methylation status is to be assessed. In other embodiments, the reagent includes, consists substantially of, or is composed of multiple probes or primers configured to hybridize with each of the tissue-specific or organ-specific target polynucleotides whose methylation status is to be assessed.
[0066] In some embodiments, one or more primers in the kits, devices, systems, or articles of the present invention comprise, are substantially composed of, or are composed of the sequences shown in SEQ ID NO: 1-730 listed in Table 2, sequences complementary to or substantially complementary to them, or any combination thereof. For each tissue-specific or organ-specific target polynucleotide listed in Table 2, the kits, devices, systems, or articles of the present invention may include, are substantially composed of, or are composed of one or more corresponding primers for said target. For example, the one or more primers may include, are substantially composed of, or are composed of the sequences shown in any of SEQ ID NO: 1-SEQ ID NO: 730, sequences complementary to or substantially complementary to them, or any combination thereof.
[0067] Table 2. Exemplary tissue-specific or organ-specific target polynucleotides In some embodiments, the kits, devices, systems, or articles of the present invention may include common primers, such as common primers for amplifying each of tissue-specific or organ-specific target polynucleotides whose methylation status is to be evaluated. Exemplary common primers may include, substantially consist of, or consist of the sequence shown in SEQ ID NO: 731 (CACTCTTTCCCTACACGACGC) or a sequence complementary to or substantially complementary to it.
[0068] The kits, devices, systems, or articles of the present invention may further include any other suitable reagents. In some embodiments, the kits, devices, systems, or articles of the present invention may further include any other suitable reagents disclosed and / or claimed in U.S. Provisional Application Serial Nos. 62 / 487,422, 62 / 487,423, US 2020 / 0048697 A1, and US 2020 / 0123538 A1, filed April 19, 2017.
[0069] For example, the kits, devices, systems or articles of the present invention may further include agents for isolating tissue-specific or organ-specific target polynucleotides from samples containing cell-free target polynucleotides from a subject (e.g., blood or plasma samples).
[0070] In another embodiment, the kit, device, system, or article of the present invention may further include reagents for preparing a library of tissue-specific or organ-specific target polynucleotides. Any suitable reagents for preparing the target library may be included. In some embodiments, the reagents for preparing a library of tissue-specific or organ-specific target polynucleotides may include enzymes, such as ligases or single-stranded DNA (ssDNA) ligases. Any suitable ssDNA ligase may be included, such as Thermophyton floccosum phage (… Thermus bacteriophage RNA ligases, such as bacteriophage TS2126 RNA ligases (e.g., CircLigase™ and CircLigase II™), or archaea RNA ligases, such as thermoautotrophic methanobacteria ( Methanobacterium thermoautotrophicum RNA ligase 1.
[0071] In yet another embodiment, the kits, devices, systems, or articles of the present invention may further include reagents for amplifying tissue-specific or organ-specific target polynucleotides or libraries of tissue-specific or organ-specific target polynucleotides. Any suitable reagents for amplifying the target or target library may be included. In some embodiments, the reagents for amplifying the target or target library may include enzymes, such as enzymes for polynucleotide amplification reactions. Exemplary polynucleotide amplification reactions include polymerase chain reaction (PCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA), ligase chain reaction (LCR), sequence-based amplification (NASBA), primer extension, rolling circle amplification (RCA), self-sustaining sequence replication (3SR), and loop-mediated isothermal amplification (LAMP).
[0072] In yet another embodiment, the kit, device, system, or article of the present invention may further include agents for purifying tissue-specific or organ-specific target polynucleotides, libraries of tissue-specific or organ-specific target polynucleotides, amplified tissue-specific or organ-specific target polynucleotides, or libraries of amplified tissue-specific or organ-specific target polynucleotides.
[0073] In yet another embodiment, the kits, devices, systems, or articles of the present invention may further include reagents for assessing the methylation status of tissue-specific or organ-specific target polynucleotides. Any suitable reagents for assessing the methylation status of a target may be included. In some embodiments, the reagents for assessing the methylation status of tissue-specific or organ-specific target polynucleotides may be reagents for polynucleotide methylation (e.g., DNA methylation), and detection methods may include mass spectrometry, methylation-specific PCR (MSP), bisulfite sequencing, HpaII microfragment enrichment assay by ligation-mediated PCR (HELP assay), Glasl hydrolysis and ligation-adaptor-dependent PCR assay (GLAD-PCR assay), restriction marker genomic scanning (RLGS), methylated DNA immunoprecipitation (MeDIP or mDIP), pyrosequencing, molecular fragmentation assay of DNA adenine methyltransferase activity, methyl-sensitive Southern blotting, and high-resolution melting (HRM) analysis.
[0074] Reagents used to assess the methylation status of tissue-specific or organ-specific target polynucleotides can be chemical agents, such as bisulfites or sodium bisulfite. Reagents used to assess the methylation status of tissue-specific or organ-specific target polynucleotides can also be biological agents, such as peptides or enzymes.
[0075] This can include any suitable enzyme. In some embodiments, the enzyme can be a methylation-sensitive restriction enzyme (MSRE). An MSRE can selectively cleave at a residue when it is unmethylated. An MSRE can also selectively cleave at a residue when it is methylated. Exemplary MSREs can be selected from the group consisting of: HpaII, SalI, SalI-HF ® , ScrFI, BbeI, NotI, SmaI, XmaI, MboI, BstBI, ClaI, MluI, NaeI, NarI, PvuI, SacII, HhaI and their combinations.
[0076] In some embodiments, the enzyme may be a polynucleotide polymerase. The polynucleotide polymerase is configured for use in polynucleotide amplification reactions, such as PCR. Any suitable polynucleotide polymerase may be included. For example, the polynucleotide polymerase may be a DNA polymerase, such as a DNA polymerase without 3' to 5' exonuclease activity.
[0077] In yet another embodiment, the kit, apparatus, system, or article of the present invention may further include a denaturing agent for denaturing double-stranded polynucleotides from a sample to obtain single-stranded polynucleotides.
[0078] In yet another embodiment, the kit, apparatus, system, or article of the present invention may further include a crowding agent for linking reactions. In one aspect, the crowding agent includes polyethylene glycol (PEG), such as PEG 4000 or PEG 6000, dextran, and / or Ficoll.
[0079] In yet another embodiment, the kit, device, system, or article of the present invention may further include a set of primers, each primer including a sequence that is reverse complementary to and / or hybridizable to the adaptor, for converting a single-stranded polynucleotide into a double-stranded polynucleotide.
[0080] In yet another embodiment, the kit, device, system, or article of the present invention may further include reagents for removing primer dimers and / or primer-adaptor duplexes.
[0081] In yet another embodiment, the kit, apparatus, system, or article of the present invention may further include primers comprising sequences specific to a target sequence (e.g., target sequences listed in Table 2) for obtaining an amplified linear double-stranded ligation product containing sequence information of the target sequence. In another aspect, the kit may further include a sequencing adaptor and / or a sample-specific barcode for sequencing the amplified linear double-stranded ligation product.
[0082] In yet another embodiment, the kit, apparatus, system, or article of the present invention may further comprise a set of isolated polynucleotides described in Part B above.
[0083] In yet another embodiment, the kit, apparatus, system, or article of the present invention may further include a reference sample and / or information of a control locus.
[0084] In yet another embodiment, the kit, device, system, or article of the present invention may further include separate containers for one or more components, such as vials, and / or instructions for using the kit, device, system, or article.
[0085] In yet another embodiment, the kit, apparatus, system, or article of manufacture of the present invention may further include a computer-readable medium containing executable instructions for obtaining a methylation metric of a sample based on methylation status assessment. The computer-readable medium may be configured to obtain any suitable form of methylation metric, for example, in the form of average methylation frequency, methylated haplotype load, unmethylated haplotype load, percentage of inconsistent reads, or combinations thereof.
[0086] In yet another embodiment, the kit, apparatus, system, or article of manufacture of the present invention may further include a computer-readable medium containing executable instructions for classification using a methylation metric. Exemplary classification algorithms may be linear discriminant analysis, logistic regression, Naive Bayes classification, perceptron classification, quadratic classification, k-nearest neighbor, augmented classification, decision tree, random forest, neural network, learned vector quantization, or support vector machine, or combinations thereof.
[0087] The kits, devices, systems, or articles of the present invention can be configured for any suitable use or purpose. For example, the kits, devices, systems, or articles of the present invention can be configured to assess the classification of samples, or to assess tissue damage or toxicity in subjects.
[0088] In some embodiments, the kit may additionally include reagents for detecting the presence of the peptide. Such reagents may be antibodies or other binding molecules that specifically bind to the peptide. In some embodiments, such antibodies or binding molecules may be able to distinguish structural variations in the peptide due to polymorphism and therefore can be used for genotyping. Antibodies or binding molecules may be labeled with detectable markers, such as radioisotopes, fluorescent compounds, bioluminescent compounds, chemiluminescent compounds, metal chelators, or enzymes. The kit may include additional reagents for performing binding assays (such as ELISA).
[0089] In some embodiments, the kit includes reagents for genotyping at least two, three, five, ten, or more biomarkers. Biomarkers may be polynucleotide biomarkers (such as cancer-associated mutations or SNPs) or peptide biomarkers (such as protein overexpression or post-translational modifications, including hyperphosphorylation or hypophosphorylation) or any combination thereof. In some embodiments, the kit may further include a surface or substrate (such as a microarray) for detecting the amplified nucleic acids.
[0090] The kit may further include a carrier device, which is spaced to house one or more container devices, such as vials, tubes, etc., in a tightly sealed manner, each container device containing a single element to be used in the method. For example, a container device may contain a probe that is detectably labeled or can be detectably labeled. Such a probe may be a polynucleotide specific to a biomarker. The kit may also have a container containing nucleotides for amplifying the target nucleic acid sequence and / or a container including a reporter device that binds to a reporter molecule (such as an enzyme-labeled, fluorescently labeled, or radioisotope-labeled molecule).
[0091] The kit typically includes the container described above and one or more other containers, which include materials deemed commercially and user-appropriate, including buffer solutions, diluents, filters, needles, syringes, and packaging inserts with instructions for use. Labels may be presented on the containers to indicate whether the composition is intended for a specific therapeutic or non-therapeutic application, and may also indicate, as described above, whether for in vivo or in vitro use.
[0092] The kit may further include a set of instructions and materials for preparing tissue or cell or body fluid samples and for preparing nucleic acids (such as ctDNA) from samples (e.g., blood samples, serum samples, or plasma samples).
[0093] The one or more tissue-specific or organ-specific target polynucleotides may comprise, consist of, or substantially consist of at least two consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, wherein the tissue-specific or organ-specific target gene encodes RNA or polypeptide specific to the subject's tissue or organ. In some embodiments, the one or more tissue-specific or organ-specific target polynucleotides may comprise, consist of, or substantially consist of at least two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, four hundred, fifty, sixty, seventy, eighty, ninety, one hundred, twenty hundred, thirty hundred, four hundred, fifty hundred, six hundred, seven hundred, eight hundred, nine hundred, one thousand, or more consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, wherein the tissue-specific or organ-specific target gene encodes RNA or polypeptide specific to the subject's tissue or organ.
[0094] In some embodiments, the tissue-specific or organ-specific target genes may be selectively or primarily expressed and / or translated in multiple tissues or organs of the subject. For example, tissue-specific or organ-specific target genes may be selectively or primarily expressed and / or translated in 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more tissues or organs of the subject. In some embodiments, the tissue-specific or organ-specific target genes are expressed and / or translated only in a single tissue or organ of the subject.
[0095] In some embodiments, the one or more tissue-specific or organ-specific target genes of the subject encode RNA that is specific to the subject's tissue or organ. In some embodiments, the one or more tissue-specific or organ-specific target genes of the subject encode polypeptides that are specific to the subject's tissue or organ.
[0096] In some embodiments, the one or more tissue-specific or organ-specific target polynucleotides / genes are listed in Table 1 or 2 below, or are located in a subgroup of the tissue-specific or organ-specific target polynucleotides / genes listed in Table 1 or 2. For example, a tissue-specific or organ-specific target polynucleotide / gene may be a single, multiple, or all of the tissue-specific or organ-specific target polynucleotides / genes of a specific tissue or organ or a selective group of tissues or organs listed in Table 1 or 2.
[0097] D. Methods used to assess cancer or tumor formation in a subject. On the other hand, this document provides an in vitro method for classifying a sample, the method comprising: a) in vitro assessing the methylation status of one or more tissue-specific or organ-specific target polynucleotides of a subject in a sample, the sample containing cellular free target polynucleotides from the subject; and b) classifying the sample into a category based on the methylation status of the one or more tissue-specific or organ-specific target polynucleotides in the sample obtained in a).
[0098] In some embodiments, step 1) of the method of the present invention includes in vitro assessment of the methylation status of one tissue-specific or organ-specific target polynucleotide of a subject in a sample, said sample comprising cell-free target polynucleotides from said subject. In some embodiments, step 1) of the method of the present invention includes in vitro assessment of the methylation status of two or more tissue-specific or organ-specific target polynucleotides of a subject in a sample, said sample comprising cell-free target polynucleotides from said subject.
[0099] In some embodiments, step 1) of the method of the present invention includes in vitro assessment of the methylation status of one or more tissue-specific target polynucleotides of a subject in a sample, said sample containing cellular free target polynucleotides from said subject.
[0100] The method of the present invention can be used for any suitable purpose. In some embodiments, the method of the present invention can be used to assess tissue damage or toxicity in a subject. In some embodiments, the method of the present invention can be used to assess damage or toxicity to connective tissue, epithelial tissue, muscle tissue, and / or nerve tissue in a subject.
[0101] In some embodiments, step 1) of the method of the present invention includes in vitro assessment of the methylation status of one or more organ-specific target polynucleotides of a subject in a sample, said sample containing cellular free target polynucleotides from said subject.
[0102] The method of the present invention can be used for any suitable purpose. In some embodiments, the method of the present invention can be used to assess organ damage or toxicity in a subject. Exemplary organs include organs from systems selected from the group consisting of: the cardiovascular system, such as the lungs, heart, blood, and blood vessels; the digestive system, such as the salivary glands, esophagus, stomach, liver, gallbladder, pancreas, intestine, colon, mesentery, rectum, and anus; and the endocrine system, such as endocrine glands, such as the hypothalamus, pituitary gland, pineal gland or pineal gland, thyroid gland, parathyroid glands, and adrenal glands. The excretory system includes organs such as glands, excretory organs, bladder, and urethra; the lymphatic system includes lymph nodes and lymphatic vessels that transport lymph, including the immune system: defending against pathogenic factors with leukocytes, tonsils, adenoids, thymus, and spleen; the exodermal system includes the skin, hair, and nails of mammals; the muscular system includes muscles; the nervous system includes the brain, spinal cord, and nerves; the reproductive system includes sex organs such as ovaries, fallopian tubes, uterus, vulva, vagina, testes, vas deferens, seminal vesicles, prostate, and penis; the respiratory system includes the pharynx, larynx, trachea, bronchi, lungs, and diaphragm; and the skeletal system includes bones, cartilage, ligaments, and tendons. In some embodiments, the method of the present invention can be used to assess damage or toxicity to the liver, kidneys, heart, stomach, lungs, testes, small intestine, colon, and / or gastrocnemius muscles of a subject.
[0103] The method of the present invention can be used to assess damage or toxicity to any suitable number of organs of a subject. In some embodiments, the method of the present invention can be used to assess damage or toxicity to a single organ of a subject. In some embodiments, the method of the present invention can be used to assess damage or toxicity to multiple organs of a subject, such as at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more organs of the subject. In some embodiments, the method of the present invention can be used to assess damage or toxicity to all organs of a subject.
[0104] The method of the present invention can be used to assess tissue or organ damage or toxicity in a subject caused or induced by any suitable cause or reason. In some embodiments, the method of the present invention can be used to assess tissue or organ damage or toxicity in a subject resulting from treatment with a substance.
[0105] Tissue or organ damage or toxicity in a subject can result from treatment with any suitable substance. In some embodiments, the substance is a drug or drug candidate. For example, the drug or drug candidate may be a chemical or small molecule drug or drug candidate. In another embodiment, the drug or drug candidate may be a biomolecular drug or drug candidate, such as a peptide, polynucleotide, or a complex thereof. In some embodiments, the drug or drug candidate is a conjugated drug or drug candidate, such as a chemical or small molecule drug or drug candidate conjugated to a peptide or antibody, polynucleotide, or a complex thereof. In some embodiments, the drug or drug candidate is a conjugated drug or drug candidate, such as a chemical or small molecule drug or drug candidate conjugated to an antibody.
[0106] The method of the present invention can be used for any suitable purpose. In some embodiments, step b) of the method of the present invention may include generating a methylation status score using a computer algorithm based on the assessed methylation status of the one or more tissue-specific or organ-specific target polynucleotides, and classifying the sample into a certain category based on the methylation status score.
[0107] This method can be used with any suitable sample, such as any suitable sample containing cell-free target polynucleotides from the subject. In some embodiments, the sample is a blood sample, urine sample, cerebrospinal fluid sample, pleural fluid sample, and saliva sample. In some embodiments, the blood sample is a serum sample, a plasma sample, or any combination thereof.
[0108] The method of this invention can be used to assess tissue and / or organ damage or toxicity in any suitable subject. For example, the method of this invention can be used to assess tissue and / or organ damage or toxicity in mammals. Mammals can be non-human mammals, such as pets, farm animals, companion animals, or laboratory animals. Mammals can also be humans.
[0109] The method of the present invention can be used to assess the methylation status of any suitable number of tissue-specific or organ-specific target polynucleotides. For example, the method of the present invention may include assessing the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides. In some embodiments, the method of the present invention may include evaluating the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides located in one or more genes listed in Table 1 or 2 (see, for example, Section C above). In some embodiments, the method of the present invention may include evaluating the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides in one or more genes located in one or more organs listed in Table 1 or 2 (see, for example, Section C above).
[0110] The methylation status of target polynucleotides can be assessed using any suitable method or reagent. For example, the methylation status of tissue-specific or organ-specific target polynucleotides can be assessed using probes or primers configured to hybridize with each target polynucleotide. In some embodiments, the methylation status of tissue-specific or organ-specific target polynucleotides is assessed using a single probe or primer configured to hybridize with the target polynucleotide. In some embodiments, the methylation status of tissue-specific or organ-specific target polynucleotides is assessed using multiple probes or primers configured to hybridize with the tissue-specific or organ-specific target polynucleotide.
[0111] In some embodiments, the one or more primers used in the method of the present invention may comprise, consist substantially of, or consist of the sequences shown in SEQ ID NO: 1-730 listed in Table 2, sequences complementary to or substantially complementary to them, or any combination thereof. For each target listed in Table 2, the one or more primers used in the method of the present invention may comprise, consist substantially of, or consist of one or more corresponding primers for said target. For example, the one or more primers may comprise, consist substantially of, or consist of the sequences shown in any of SEQ ID NO: 1-SEQ ID NO: 730, sequences complementary to or substantially complementary to them, or any combination thereof.
[0112] The method of the present invention may further include using a common primer to amplify each of the target polynucleotides whose methylation status is to be evaluated. Exemplary common primers may include, consist substantially of, or consist of the sequence shown in SEQ ID NO: 731 (CACTCTTTCCCTACACGACGC) or a sequence complementary to or substantially complementary to it.
[0113] The method of the present invention may further include any other suitable steps. In some embodiments, the method of the present invention may further include any other suitable steps disclosed and / or claimed in U.S. Provisional Application Serial Nos. 62 / 487,422, 62 / 487,423, US 2020 / 0048697 A1, and US 2020 / 0123538A1, filed April 19, 2017. For example, the techniques and steps disclosed and / or claimed in U.S. Provisional Application Serial Nos. 62 / 487,423 and US 2020 / 0123538A1 for constructing single-stranded polynucleotides, converting single-stranded polynucleotide libraries into double-stranded polynucleotide libraries, semi-targeted amplification of double-stranded polynucleotide libraries, and construction of sequence libraries and analysis of sequencing reads can be used to obtain and / or prepare the target polynucleotide to be analyzed.
[0114] For example, the method of the present invention may further include isolating tissue-specific or organ-specific target polynucleotides from a sample (e.g., a blood sample).
[0115] In another embodiment, the method of the present invention may further include preparing a library of tissue-specific or organ-specific target polynucleotides. Any suitable reagent for preparing a library of tissue-specific or organ-specific target polynucleotides may be used. In some embodiments, the reagent for preparing a library of tissue-specific or organ-specific target polynucleotides may include enzymes, such as ligases or single-stranded DNA (ssDNA) ligases. Any suitable ssDNA ligase may be included, such as those from the genus *Thermophyton*. Thermus Phage RNA ligases, such as phage TS2126 RNA ligases (e.g., CircLigase™ and CircLigase II™), or archaebacterium RNA ligases, such as thermoautotrophic methanobacteria (… Methanobacterium thermoautotrophicum RNA ligase 1.
[0116] In another embodiment, the method of the present invention may further include amplifying tissue-specific or organ-specific target polynucleotides. In some embodiments, the reagents used for amplifying tissue-specific or organ-specific target polynucleotides or libraries of tissue-specific or organ-specific target polynucleotides may include enzymes, such as enzymes for polynucleotide amplification reactions. Exemplary polynucleotide amplification reactions include polymerase chain reaction (PCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA), ligase chain reaction (LCR), sequence-based amplification (NASBA), primer extension, rolling circle amplification (RCA), self-sustaining sequence replication (3SR), and loop-mediated isothermal amplification (LAMP).
[0117] In yet another embodiment, the method of the present invention may further include purifying tissue-specific or organ-specific target polynucleotides, a library of tissue-specific or organ-specific target polynucleotides, amplifying tissue-specific or organ-specific target polynucleotides, or a library of amplified tissue-specific or organ-specific target polynucleotides.
[0118] The methylation status of tissue-specific or organ-specific target polynucleotides can be assessed using any suitable method and / or reagent. In some embodiments, the methylation status of tissue-specific or organ-specific target polynucleotides can be assessed using mass spectrometry, methylation-specific PCR (MSP), methylation-sensitive sequencing (e.g., bisulfite sequencing), HpaII microfragment enrichment assays via ligation-mediated PCR (HELP assays), Glal hydrolysis and ligation adaptor-dependent PCR assays (GLAD-PCR assays), restriction marker genomic scanning (RLGS), methylated DNA immunoprecipitation (MeDIP or mDIP), pyrosequencing, molecular fragmentation assays for DNA adenine methyltransferase activity, methyl-sensitive Southern blotting, or high-resolution melting (HRM) analysis.
[0119] In some embodiments, chemical agents (e.g., bisulfite or sodium bisulfite) can be used to assess the methylation status of tissue-specific or organ-specific target polynucleotides. In some embodiments, biological agents (e.g., peptides or enzymes) can be used to assess the methylation status of tissue-specific or organ-specific target polynucleotides.
[0120] Any suitable enzyme can be used. In some embodiments, the enzyme can be a methylation-sensitive restriction enzyme (MSRE). An MSRE can selectively cleave residues when they are unmethylated. An MSRE can also selectively cleave residues when they are methylated. Exemplary MSREs can be selected from the group consisting of: HpaII, SalI, SalI-HF ® , ScrFI, BbeI, NotI, SmaI, XmaI, MboI, BstBI, ClaI, MluI, NaeI, NarI, PvuI, SacII, HhaI and their combinations.
[0121] In some implementations, the enzyme may be a polynucleotide polymerase. Polynucleotide polymerases can be used for polynucleotide amplification reactions, such as PCR. Any suitable polynucleotide polymerase can be used. For example, the polynucleotide polymerase may be a DNA polymerase, such as a DNA polymerase without 3' to 5' exonuclease activity.
[0122] In some implementations, the methylation status of tissue-specific or organ-specific target polynucleotides can be assessed using methylation-sensitive sequencing (e.g., bisulfite sequencing). Bisulfite conversion is a method that uses bisulfite to determine the methylation pattern of DNA. DNA methylation is a biochemical process involving the addition of a methyl group to a cytosine or adenine DNA nucleotide. As cells divide and differentiate from embryonic stem cells into specific tissues, DNA methylation stably alters gene expression within the cell. In bisulfite conversion, the target nucleic acid is first treated with a bisulfite reagent that specifically converts unmethylated cytosine to uracil, without affecting methylated cytosine. One result of bisulfite conversion is the disruption of the original target's double-stranded conformation due to loss of sequence complementarity. During sample preparation and analysis or diagnostic testing, the target sequence exists as two separate single-stranded DNA sequences. The target nucleic acid sequence is also typically present at very low concentrations. This is a particularly important consideration for circulating tumor DNA (also known as "cell-free tumor DNA" or "ctDNA"), as its concentration in circulation is typically low and the variant allele fraction is very low.
[0123] Methylation-sensitive sequencing can be performed using any suitable form. For example, methylation-sensitive sequencing can be performed using a group consisting of: Maxam-Gilbert sequencing, chain termination sequencing, shotgun sequencing, bridge PCR, single-molecule real-time sequencing, ion semiconductor (ion-fluid current sequencing), synthesis sequencing, ligation sequencing (SOLiD sequencing), chain termination (Sanger sequencing), massively parallel signature sequencing (MPSS), polymerase cloning sequencing, 454 pyrosequencing, Illumina (Solexa) sequencing, DNA nanosphere sequencing, Heliscope single-molecule sequencing, single-molecule real-time (SMRT) sequencing, nanopore DNA sequencing, tunneling current DNA sequencing, hybridization sequencing, mass spectrometry sequencing, microfluidic Sanger sequencing, microscopy-based techniques, RNAP sequencing, and in vitro viral high-throughput sequencing.
[0124] In some embodiments, the method of the present invention may further include, prior to methylation-sensitive sequencing (e.g., bisulfite sequencing), obtaining a library of linear single-stranded ligation products, each linear single-stranded ligation product comprising a linear single-stranded target polynucleotide linked to an adaptor, said adaptor comprising a unique molecular identifier (UMI) sequence that tags the single-stranded target polynucleotide linked to the adaptor. The sequencing reads from tissue-specific or organ-specific target polynucleotides may first undergo adaptor trimming to remove any adaptor sequences originating from the library construction process, thereby obtaining trimmed sequencing reads. The trimmed sequencing reads may be mapped to a reference genome, such as the human reference genome, using an alignment program to obtain aligned read files.
[0125] The methylation status of one, more, or each of the tissue-specific or organ-specific target polynucleotides can be assessed. In some embodiments, the methylation status of each of the tissue-specific or organ-specific target polynucleotides can be assessed.
[0126] In some embodiments, the methylation status of each of the tissue-specific or organ-specific target polynucleotides can be assessed to obtain methylation metrics, such as average methylation frequency, methylated haplotype load, unmethylated haplotype load, percentage of inconsistent reads, or combinations thereof. In some embodiments, methylation metrics from each of the tissue-specific or organ-specific target polynucleotides are used to assess the methylation status of a sample (e.g., a blood sample).
[0127] The methylation status of a sample can be assessed using methylation measures from each of the tissue-specific or organ-specific target polynucleotides. Methylation measures can be analyzed or used in any suitable manner. For example, the methylation measure of each of the tissue-specific or organ-specific target polynucleotides can be compared to a threshold or reference value to assess the methylation status of a sample (e.g., a blood sample).
[0128] In another embodiment, a numerical methylation matrix can be calculated using methylation measures from each of the tissue-specific or organ-specific target polynucleotides to assess the methylation status of a sample (e.g., a blood sample). The numerical methylation matrix can be in any suitable format. In some embodiments, the numerical methylation matrix from a sample (e.g., a blood sample) may include a single numerical number or value. In other embodiments, the numerical methylation matrix from a sample (e.g., a blood sample) may include multiple numerical numbers or values.
[0129] Numerical methylation matrices can be obtained or computed using any suitable formula or algorithm. In some implementations, classification algorithms can be used to compute numerical methylation matrices, such as linear discriminant analysis, logistic regression, naïve bayes classification, perceptron classification, quadratic classification, k-nearest neighbors, boosting, decision trees, random forests, neural networks, learned vector quantization, or support vector machines.
[0130] A methylation matrix can be used in any suitable manner to assess the methylation status of a sample. For example, the methylation matrix can be compared to a threshold or reference value to assess the methylation status of a sample (e.g., a blood sample).
[0131] The methylation status of at least two tissue-specific or organ-specific target polynucleotides from multiple samples (e.g., multiple samples from multiple subjects) can be evaluated sequentially or simultaneously. In some embodiments, the methylation status of at least two target polynucleotides from multiple samples (e.g., multiple samples from multiple subjects) can be evaluated sequentially. For example, the methylation status or numerical ranges or subranges of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides listed in Table 1 or 2 can be evaluated sequentially. In other embodiments, the methylation status of at least two target polynucleotides from multiple samples (e.g., multiple samples from multiple subjects) can be evaluated simultaneously. For example, the methylation status or numerical ranges or subranges of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides listed in Table 1 or 2 can be evaluated simultaneously.
[0132] In some embodiments, a computer is used to obtain a methylation measure for each target polynucleotide. In other embodiments, a computer is used to obtain a methylation matrix of the sample based on the methylation measure from each target polynucleotide.
[0133] In some implementations, a methylation matrix of a sample (e.g., a blood sample) is obtained using a computer based on methylation measurements from each of the tissue-specific or organ-specific target polynucleotides.
[0134] In some implementations, the methylation status of at least two tissue-specific or organ-specific target polynucleotides from multiple samples (e.g., multiple samples from multiple subjects) is evaluated sequentially or simultaneously.
[0135] The test of the present invention can have any suitable sensitivity. For example, the test of the present invention can have a sensitivity of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.999%, 99.9999%, or 100%. In some embodiments, the method of the present invention is more sensitive than the method of assessing tissue or organ damage or toxicity in a subject by measuring another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity). In some embodiments, the method of the present invention is more sensitive to assessing organ damage or toxicity in subjects than to assessing organ damage or toxicity by measuring another biomarker (e.g., the gold standard biomarker for assessing organ damage or toxicity).
[0136] The test of the present invention can have any suitable specificity. For example, the test of the present invention can have a specificity of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.999%, 99.9999%, or 100%. In some embodiments, the method of the present invention has a higher specificity for assessing tissue or organ damage or toxicity in a subject than the method of assessing tissue or organ damage or toxicity in a subject by measuring another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity). In some embodiments, the method of the present invention is more specific for assessing organ damage or toxicity in a subject than for assessing organ damage or toxicity in a subject by measuring another biomarker (e.g., the gold standard biomarker for assessing tissue damage or toxicity).
[0137] The method of the present invention can be used for any suitable purpose. For example, the method of the present invention can be used to assess tissue or organ damage or toxicity in a subject at a stage where the damage or toxicity cannot be detected by another assay of another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity). In some embodiments, the method of the present invention can be used to assess tissue damage or toxicity in a subject at a stage where the damage or toxicity cannot be detected by another assay of another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity). In some embodiments, the method of the present invention can be used to assess organ damage or toxicity in a subject at a stage where the damage or toxicity cannot be detected by another assay of another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity).
[0138] The method of the present invention can be used to assess damage or toxicity to multiple tissues and / or organs (e.g., all tissues and / or organs of the subject) in a single test. In some embodiments, the method of the present invention can be used to assess damage or toxicity to multiple tissues (e.g., all tissues of the subject) in a single test. In some embodiments, the method of the present invention can be used to assess damage or toxicity to multiple organs (e.g., all organs of the subject) in a single test.
[0139] In some embodiments, the method of the present invention may further include assessing tissue or organ damage or toxicity in a subject by measuring another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity).
[0140] In some embodiments, the method of the present invention can be used to assess tissue or organ damage or toxicity in animal subjects during animal testing.
[0141] In some embodiments, the method of the present invention can be used to assess tissue or organ damage or toxicity over time from a single animal.
[0142] In some embodiments, the methods of the present invention can be used to assess tissue or organ damage or toxicity in human subjects, for example, in preclinical or clinical studies.
[0143] In some embodiments, the methods of the present invention can be used for the diagnosis, prognosis, stratification, risk assessment, or treatment monitoring of tissue and / or organ damage or toxicity in subjects.
[0144] In some embodiments, the methods of the present invention can be used to assess liver injury or toxicity in a subject. In these methods or tests, the tissue-specific or organ-specific target polynucleotides: a) may be located in one or more liver-specific genes as listed in Table 1 or 2; or c) may include, consist substantially of, or consist of one or more sequences shown in SEQ ID NO: 246-730 or sequences complementary to or substantially complementary to them.
[0145] In some embodiments, the methods of the present invention can be used to assess testicular injury or toxicity in a subject. In these methods or tests, tissue-specific or organ-specific target polynucleotides: a) may be located in genes selected from the group consisting of: B3galt1, Cacng5, Ccdc162, Cdc23, Cdca2, Ceacam5, Cnot4, Crybg1, Ddr1, Dpysl4, Enc1, Fam69b, Hs6st3, Ins1, Maml2, Midn, Obox5, Pax7, Pdlim4, Rtn4ip1, Siglec15, Slc16a3, Slc22a4, Smim23, Snx33, Syndig1, Tagln, Tcf3, Trpc7 and TTC8 b) may be located in one or more testis-specific genes listed in Table 1 or 2; or c) may include, consist of, or consist of one or more sequences shown in SEQ ID NO: 1-245 or sequences complementary to or substantially complementary to them.
[0146] The one or more tissue-specific or organ-specific target polynucleotides may comprise, consist of, or substantially consist of at least two consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, wherein the tissue-specific or organ-specific target gene encodes RNA or polypeptide specific to the subject's tissue or organ. In some embodiments, the one or more tissue-specific or organ-specific target polynucleotides may comprise, consist of, or substantially consist of at least two, three, four, five, six, seven, eight, nine, ten, twenty, thirty, four hundred, fifty, sixty, seventy, eighty, ninety, one hundred, twenty hundred, thirty hundred, four hundred, fifty hundred, six hundred, seven hundred, eight hundred, nine hundred, one thousand, or more consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, wherein the tissue-specific or organ-specific target gene encodes RNA or polypeptide specific to the subject's tissue or organ.
[0147] In some embodiments, the tissue-specific or organ-specific target genes may be selectively or primarily expressed and / or translated in multiple tissues or organs of the subject. For example, tissue-specific or organ-specific target genes may be selectively or primarily expressed and / or translated in 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more tissues or organs of the subject. In some embodiments, the tissue-specific or organ-specific target genes are expressed and / or translated only in a single tissue or organ of the subject.
[0148] In some embodiments, the one or more tissue-specific or organ-specific target genes of the subject encode RNA that is specific to the subject's tissue or organ. In some embodiments, the one or more tissue-specific or organ-specific target genes of the subject encode polypeptides that are specific to the subject's tissue or organ.
[0149] In some embodiments, the one or more tissue-specific or organ-specific target polynucleotides / genes are listed in Table 1 or 2 below, or are located in a subgroup of the tissue-specific or organ-specific target polynucleotides / genes listed in Table 1 or 2. For example, a tissue-specific or organ-specific target polynucleotide / gene may be a single, multiple, or all of the tissue-specific or organ-specific target polynucleotides / genes of a specific tissue or organ or a selective group of tissues or organs listed in Table 1 or 2.
[0150] E. Exemplary Data Analysis Methods Generation of RRBS libraries for sequencing (MONOD) In some implementations, DNA is first extracted from the sample of interest using a commercial DNA extraction kit such as QIAGEN DNeasy or ThermoFisher MagMax Total Nucleic Acid Extraction Kit. The isolated DNA is then treated with a methylation-insensitive restriction enzyme (e.g., MspI) to obtain fragmented DNA with sticky overhangs that match the restriction digestion sites. Prior to this step, the DNA can optionally be end-repaired and A-tailed using an enzymatic process to generate A-overhangs, or the untreated restriction digestion sites can be retained as overhangs. A specialized RRBS sequencing adaptor is then ligated to the ends of each DNA fragment using a DNA ligase; these sequencing adaptors contain 5'-methylcytosine instead of unmethylated cytosine to protect the adaptor region from bisulfite conversion. The ligated molecules are then treated with sodium bisulfite, which converts all unmethylated cytosine to uracil and retains the methylated cytosine intact as cytosine, and the treated molecules are eluted using a DNA cleaning column. The library was then loaded onto an NGS sequencer (such as an Illumina NextSeq 500) and sequenced according to the manufacturer’s instructions.
[0151] Other bisulfite library construction methods can also be used instead of RRBS, such as WGBS (in which random fragmentation enzymes such as DNase I are used instead of restriction enzymes to fragment DNA) or Singlera's patented TitanSeq method (which uses single-strand ligation and a semi-PCR method after bisulfite conversion).
[0152] Data analysis methods Preprocessing In some implementations, the sequencing reads are first trimmed using trimming programs such as Cutadapt (http: / / journal.embnet.org / index.php / embnetjournal / article / view / 200 / 479) or Trimmomatic (https: / / www.ncbi.nlm.nih.gov / pubmed / 24695404) to remove any synthetic adapter sequences originating from the sequencing library construction process. The trimmed reads are then mapped to a human reference genome using alignment programs such as Bowtie (http: / / bowtie-bio.sourceforge.net / index.shtml), Bowtie2 (http: / / bowtie-bio.sourceforge.net / bowtie2 / index.shtml), or BWA (http: / / bio-bwa.sourceforge.net). The resulting aligned read files are then sorted and indexed using Samtools (https: / / github.com / samtools / samtools). The reads are then grouped into sets corresponding to each target region that can be used for methylation metric calculations.
[0153] methylation measurement calculation In some implementations, for each target, a “methylation metric” representing the methylation status of a single region is calculated using the aligned reads. Four metrics that can be used are average methylation frequency (AMF), methylated haplotype load (MHL), unmethylated haplotype load (UMHL), and percentage of inconsistent reads (PDR).
[0154] The average methylation frequency is calculated by summing the number of cytosine bases observed at CpG sites within the target region and dividing by the number of cytosine and thymine bases observed at CpG sites within the target region. in N It is the number of reads within the target region. i It is the first in the target region i Each paragraph, C i It is in the i The number of cytosines observed in each read segment, and T i It is in the i The number of thymine observed in each reading segment.
[0155] The methylation haplotype load is calculated by obtaining all possible substrings of adjacent CpG sites within the target region and calculating the weighted sum of the fractions of fully methylated reads within each substring: in n It is the number of CpG sites within the target region. L i It is the length of the current substring. C i It includes lengths of L i The number of all cytosine reads at CpG sites within the substring, and N i It includes lengths of L i The number of segments to read from the substring.
[0156] Unmethylated haplotype load is calculated by acquiring all possible substrings of adjacent CpG sites within the target region and calculating the weighted sum of the fractions of unmethylated reads within each substring: in n It is the number of CpG sites within the target region. L i It is the length of the current substring. T i It includes lengths of L i The number of all thymine reads at CpG sites within the substring, and N i It includes lengths of L i The number of segments to be read from the substring.
[0157] The percentage of inconsistent reads is calculated by subtracting the percentage of reads containing all cytosine or all thymine at CpG sites within the target region from 100: in N i It is the number of reads within the target region. C i It is the number of cytosine reads including all covered CpG sites, and T i It is the number of thymine reads that include all covered CpG sites.
[0158] Organizational characteristics derivation In some implementations, to classify plasma samples as containing methylation signatures derived from individual tissue samples, a reference tissue methylation database must be generated for the target genome of interest. Tissue samples from a variety of cells and organs (including but not limited to colon, calf muscle, heart, kidney, liver, lung, lymphocytes, small intestine, stomach, thymus, and testis) are processed using DNA methylation assays and bioinformatics. These reference methylation measures (AMF, MHL, UMHL, and PDR) are stored as a reference database for classifying cell-free DNA from individual plasma samples.
[0159] Classification In some implementations, a numerical matrix is calculated using the methylation measure of each target region (one row for each target region, one column for each sample, and values representing the methylation measure of the region and sample). The samples are then classified using classification algorithms such as logistic regression, k-nearest neighbors, random forest, or support vector machines against reference tissue features.
[0160] Logistic regression classification involves fitting a curve representing the probability of samples containing DNA from the tissue type of interest to a weighted sum of methylation measures using a known set of samples. Least squares regression is used on data from samples with known categories to estimate the parameters of the following equation: in n It is a collection of target regions. i This is the current target area. M i It is the first i Methylation metric values for each target region ß i It is the first i The least squares parameters of each target region, and p This is the probability that a sample contains DNA from the tissue type of interest. Once the parameters of this equation are derived using known samples, the probability can be calculated by using the derived equation to calculate a weighted sum of methylation measures and comparing it to a threshold, thereby classifying unknown samples as DNA-positive or DNA-negative from tissue origin.
[0161] The K-nearest neighbor algorithm uses unknown samples and their known class neighbors. k The distance between the methylation metrics of nearest neighbors is used to classify unknown samples. First, the distance between the current sample and the methylation metrics of all other samples (in this case, the Euclidean distance) is calculated: in N It is a set of known samples.i These are currently known samples. n It is a collection of target regions. j This is the current target area. M j It is the first j Methylation metric values of unknown samples in each target region m ij It is the first j The methylation metric of the i-th known sample in each target region, and E i Is the current sample and the first i The Euclidean distance between known samples. Using the minimum Euclidean distance... k The category of an unknown sample is determined by the category of a known sample; the category that appears most frequently is assigned to the unknown sample. In this case, the unknown sample is compared with a reference library of known tissue samples and baseline plasma DNA.
[0162] Random forest classification involves creating multiple decision trees using randomly selected subsets of samples and target regions with known classes; then, for each individual decision tree, the methylation metric of unknown samples is used, and classification is performed using majority voting. For example, using known data, the following three decision trees can be constructed: Unknown samples containing MHL values ( MHL 1 0.6, MHL 2 0.08, MHL 3 (0.36) will be classified as liver because it will have two votes in favor of liver and two votes in favor of no signal.
[0163] Support vector machines construct hyperplanes between known samples of different classes, maximizing the distance between each known sample and the hyperplane. This plane is then used as an "assigner" to classify unknown samples, with samples falling on different sides of the plane being classified differently. To illustrate an embodiment using two target regions, the methylation metric of known samples is plotted in space, and hyperplanes are plotted between different groups (see [link to example]). Figure 1X1 is the methylation metric of the first target region, X2 is the methylation metric of the second target region, reference tissue samples are plotted in black, known signal-free samples are plotted in white, and the black line represents the hyperplane. To classify unknown samples (shown in orange), the methylation metric is compared to the hyperplane; if the sample falls on the same side as a known signal-free sample (as shown here), the sample is classified as "signal-free". Figure 1 The image is taken from (Wikipedia: https: / / en.wikipedia.org / wiki / Support_vector_machine) for illustrative purposes only and does not represent any analysis of DNA methylation status or assessment of tissue and / or organ damage or toxicity.
[0164] F. Exemplary polynucleotide fragment analysis via library construction and polynucleotide sequencing On the one hand, the target (or template) polynucleotide of the method of the present invention is a fragmented polynucleotide, for example, in the range of about 100 residues to about 1,000 residues, and in some embodiments, in the range of about 150 residues to about 400 residues.
[0165] The target DNA or template DNA may include normal genomic DNA, chromosomal DNA, extrachromosomal DNA (such as mitochondrial DNA), or fragments thereof. In other embodiments, the target DNA or template DNA is processed DNA, for example, DNA that has undergone enzymatic digestion, cross-linking, chemical or physical shearing, bisulfite conversion, and / or degradation.
[0166] Bisulfite conversion is a method that uses bisulfite to determine the methylation pattern of DNA. DNA methylation is a biochemical process involving the addition of a methyl group to a cytosine or adenine DNA nucleotide. As cells divide and differentiate from embryonic stem cells into specific tissues, DNA methylation stably alters gene expression within the cell. In bisulfite conversion, the target nucleic acid is first treated with a bisulfite reagent that specifically converts unmethylated cytosine to uracil without the effects of methylated cytosine. One result of bisulfite conversion is the disruption of the original target's double-stranded conformation due to loss of sequence complementarity. During sample preparation and analysis or diagnostic testing, the target sequence exists as two separate single-stranded DNA sequences. The target nucleic acid sequence is also typically present at very low concentrations. This is a particularly important consideration for circulating tumor DNA (also known as "cell-free tumor DNA" or "ctDNA"), as its concentration in circulation is typically low and the variant allele fraction is very low.
[0167] In some embodiments, the nucleic acid molecules of interest disclosed herein are cell-free DNA, such as cell-free fetal DNA (also known as “cfDNA”) or ctDNA. cfDNA circulates in the body of a pregnant mother (e.g., in the blood) and represents the fetal genome, while ctDNA circulates in the body of a cancer patient (e.g., in the blood) and is typically pre-fragmented. In other embodiments, the nucleic acid molecules of interest disclosed herein are ancient and / or damaged DNA, for example, due to storage under destructive conditions, such as in formalin-fixed or partially digested samples.
[0168] When cancer cells die, they release DNA into the bloodstream. This DNA, called circulating tumor DNA (ctDNA), is highly fragmented, with an average length of about 150 base pairs. Once white blood cells are removed, ctDNA typically comprises a very small fraction of the remaining plasma DNA; for example, ctDNA may make up less than about 10% of plasma DNA. Typically, this percentage is less than about 1%, such as less than about 0.5% or less than about 0.01%. Furthermore, the total amount of plasma DNA is usually very low, for example, about 10 ng / mL of plasma.
[0169] Variants in ctDNA can be queried using various methods, including next-generation sequencing. Due to the low ratio of ctDNA to plasma DNA, and errors in PCR and sequencing, it is difficult to query variants with high confidence. Unique molecular identifiers (UMIs) are typically used to label the original molecules, allowing any variants seen to be compared to a common sequence. This is an effective way to distinguish between true positives and false positives. If a variant matches the common sequence, it is a true positive. Otherwise, it is removed from the analysis. Furthermore, it is important to convert a high percentage of the original molecules into sequencing libraries to maintain high sensitivity, meaning that variants are not missed due to loss. Therefore, ligation efficiency is extremely important during library construction.
[0170] On one hand, this paper provides a technique that significantly improves ligation efficiency while still targeting selected regions of the genome. In one implementation, the polynucleotide to be sequenced (e.g., ctDNA) is first dephosphorylated to remove the 5' phosphate ester, preventing the ctDNA from ligating to itself. The ctDNA is then denatured, ensuring all DNA is single-stranded. Circligase™, a single-stranded DNA ligase, is used to ligate the adaptor to the 3' end of the ctDNA. On one hand, the adaptor includes two specific bases at the 5' end to optimize ligation efficiency, followed by UMI. On the other hand, the 3' end of the adaptor contains a carbon spacer to prevent self-ligation. On the other hand, a congesting agent such as PEG 4000 is used to further optimize the ligation reaction. On the other hand, after ligation, a primer that is reverse complementary to the adaptor is used to double-strand the molecule. This allows for efficient removal of excess unligated adaptors by standard purification without removing usable DNA.
[0171] On one hand, the DNA is then amplified using semi-targeted PCR. One primer is inversely complementary to the adaptor, while another primer (e.g., as part of a primer pool) anneals to a specific target region of the genome. Specific primers are engineered to minimize primer-dimer interactions and off-target annealing. On the other hand, due to the small DNA size, target-specific primers are further optimized to closely approximate specific variants. After another cleaning, PCR is performed to add full-length sequencing adaptors and barcodes. The final library is then sequenced, for example, on an Illumina machine.
[0172] On the one hand, despite a relatively small target region of approximately 30,000 bp, semi-targeted PCR results in an enrichment of the original molecule >approximately 40,000-fold. On the other hand, the overall conversion rate of the method of the present invention is at least 60%, meaning that at least approximately 3 times more of the original molecules are converted into sequenceable material compared to standard library construction and hybridization capture. In other embodiments, the overall conversion rate is between approximately 60% and approximately 70%, between approximately 70% and approximately 80%, between approximately 80% and approximately 90%, or greater than 90%. On the other hand, the method of the present invention is therefore able to accurately invoke genetic or genomic variants, such as SNVs, insertions / deletions, CNVs, and fusions, with extremely low allele fractions (e.g., as low as 0.01%). In other aspects, the allele fractions of the genetic or genomic variants are approximately 0.05%, approximately 0.1%, approximately 0.5%, approximately 1%, or approximately 2%.
[0173] The following sections describe some steps of the method of the present invention in more detail.
[0174] Single-stranded polynucleotide libraries and their construction methods Library construction for next-generation sequencing (e.g., for ctDNA) typically consists of several steps, including end repair, A-tailing, and double-strand ligation of adaptor molecules. These ligated molecules can then be enriched 1000–2000-fold at certain genomic regions using hybridization capture. Despite some improvements in library construction over the past few years, the process remains inefficient, resulting in the loss of many original molecules during various steps. Double-strand ligation efficiency remains low, with approximately 20–30% of molecules being correctly ligated. Additionally, many molecules are lost during purification and hybridization capture steps, resulting in a final conversion rate of approximately 10–20%. Sensitivity remains low when querying for low-allele fraction variants found in ctDNA. This limits accuracy when calling low-allele fraction mutants, as the low efficiency leads to a loss of sensitivity when examining libraries with low allele fractions.
[0175] Furthermore, the small size of certain polynucleotides (such as ctDNA) prevents the use of tag-based library construction. For example, polynucleotides are first tagged (e.g., with biotin) to generate a targeted library, and then enriched by capture tags (e.g., via streptavidin). In this way, the library of the region of interest can be enriched by approximately 1000–2000-fold. Finally, PCR is performed to amplify and index the molecule for sequencing. However, PCR-based methods have proven difficult to add UMIs to the original molecule and result in high error rates.
[0176] On the one hand, the compositions, kits, and methods described herein address the aforementioned problems. In some embodiments, the compositions, kits, and methods can be used for sequencing nucleic acid molecules, including but not limited to constructing various libraries, performing various amplification reactions (such as PCR and / or primer extension), purifying constructed libraries, and analyzing sequencing reads.
[0177] In some respects, sequencing libraries can be prepared, for example, from samples containing fragmented polynucleotides (such as fragmented DNA). On one hand, the sample is a naturally occurring sample obtained directly from the subject, such as tissue fluid or bodily fluids, including but not limited to blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, sweat, semen, sputum, tears, mucus, or amniotic fluid. In other respects, sequencing libraries can be prepared by forming DNA fragments (e.g., by cutting DNA) and linking the adaptor of this article to the DNA fragment. In a particular embodiment, the fragmented polynucleotides and the adaptor are single-stranded.
[0178] Fragments (e.g., ctDNA or fragments formed by fragmenting longer DNA strands) are sometimes referred to as “insertions” because they can be “inserted” or linked adjacently to adaptors (such as the single-stranded adaptors disclosed herein). RNA molecules can also be sequenced, for example by reverse transcription of RNA molecules to form DNA molecules linked to adaptors.
[0179] On one hand, a method is provided that includes ligating a set of adaptors to a library of single-stranded polynucleotides, wherein the ligation is catalyzed by a single-stranded DNA (ssDNA) ligase. As used herein, ssDNA ligases are capable of ligating the ends of ssDNA in the absence of complementary sequences. For example, CircLigase™ ssDNA ligase and CircLigase™ II ssDNA ligase are both thermostable ligases commonly used to catalyze intramolecular ligation (i.e., circularization) of ssDNA templates having 5'-phosphate and 3'-hydroxyl groups. T4 DNA ligase and Ampligase are also mentioned. ® Compared to DNA ligases, ssDNA ligases ligate the ends of ssDNA in the absence of complementary sequences. Therefore, the enzyme can be used to prepare circular ssDNA molecules from linear ssDNA. Circular ssDNA molecules can then be used as substrates for rolling circle replication or rolling circle transcription. In addition to its activity with ssDNA, CircLigase enzymes also possess the activity of ligating single-stranded nucleic acids with 3'-hydroxyribonucleotides and 5'-phosphorylated ribonucleotides or deoxyribonucleotides.
[0180] Both CircLigase™ ssDNA ligase and CircLigase™ II ssDNA ligase can be used in this disclosure. The difference between the two enzymes is that CircLigase I is adenosinetized to a much lower degree than CircLigase II and requires ATP for optimal activity. CircLigase I recirculates ssDNA in the presence of ATP. CircLigase II is almost 100% adenosinetized, therefore there is no need to add ATP to the reaction buffer. CircLigase II functions as a stoichiometric reaction, in which the enzyme binds to the 5' end of the adenosinetized oligonucleotide at the enzyme active site, and then ligates the oligonucleotide and terminates the reaction. Because the reaction does not involve ATP, CircLigase II operates in a 1:1 enzyme:oligonucleotide conformation. Once cyclization is complete, the circular ssDNA is released from the active site, and the reaction stops.
[0181] On one hand, each single-stranded polynucleotide is blocked at the 5' end to prevent ligation at the 5' end. Each adaptor includes a unique molecular identifier (UMI) sequence that marks the single-stranded polynucleotide to which the adaptor is attached. Each adaptor is blocked at the 3' end to prevent ligation at the 3' end. The 5' end of the adaptor is ligated to the 3' end of the single-stranded polynucleotide by ssDNA ligase to form a linear ligation product, thereby obtaining a library of linear single-stranded ligation products. Template-independent circularization of single-stranded DNA is described in WO2010 / 094040 A1, the disclosure of which is incorporated herein by reference in its entirety. However, WO2010 / 094040 A1 only discloses intramolecular ligation (e.g., circularization) of single-stranded polynucleotides.
[0182] Therefore, the method of the present invention uses ssDNA ligases, such as CircLigase or CircLigaseII, in an unconventional manner. Instead of circularization, the ligation method of the present invention aims to produce a linear ligation product between a single-stranded target polynucleotide and an adaptor molecule. In one aspect, this disclosure uses ssDNA ligases for intramolecular ligation, for example, for ligating an adaptor to a single-stranded polynucleotide. To do this, the single-stranded polynucleotide is blocked at its 5' end to prevent circularization. This prevents intramolecular ligation of the 3' end of the ssDNA to its own 5' end, and intermolecular ligation of the 3' end of one ssDNA to the 5' end of another ssDNA within the same library. Therefore, both the circularization of the single-stranded polynucleotide and the formation of a linear tandem (including the single-stranded polynucleotide and / or the adaptor) are prevented during the ligation reaction. Figure 2 As shown, blocking of each single-stranded polynucleotide may include dephosphorylation at its 5' end to prevent linkage at said end.
[0183] On the other hand, each adaptor is blocked at its 3' end to prevent ligation at the 3' end. This prevents intramolecular ligation of the 3' end of the adaptor to its own 5' end, as well as intermolecular ligation of the 3' end of one adaptor molecule to the 5' end of another. The blocking of each adaptor can include a carbon spacer, ddCTP, ddATP, ddTTP, ddGTP, hexanediol, triethylene glycol (TEG), and / or hexaethylene glycol to prevent ligation at its 3' end. Therefore, on the one hand, both cyclization of single-stranded adaptors and the formation of linear tandem structures (including single-stranded polynucleotides and / or adaptors) are prevented during the ligation reaction.
[0184] The adaptor can include one or more copies of one or more spacers in any suitable combination. For example, Gansauge and Meyer disclosed an adaptor that includes ten copies of a C3 spacer and a biotinylated TEG spacer. Gansauge and Meyer (2013), “Single-stranded DNA library preparation for the sequencing of ancient or damaged DNA”, Nature Protocols (Nature Protocols). Nature Protocols The reference, 8(4):737-48, is incorporated herein by reference in its entirety. However, in this reference, the ligated ssDNA needs to be captured immediately after ligation via biotin-streptavidin interaction. This step may result in significant loss of ssDNA molecules in the library. Then, in the reference, the captured ssDNA is converted to dsDNA while the ssDNA remains captured on beads.
[0185] like Figure 2 As shown, this disclosure does not require immediate capture of the ligated ssDNA after ligation. Instead, the ligated ssDNA remains in the ligation reaction volume as it is converted to dsDNA.
[0186] On the one hand, the ssDNA in the library exhibits high ligation efficiency; for example, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% of the single-stranded polynucleotides in the sample are ligated to the adaptor. In a particular embodiment, the ligation efficiency is about 80%. Due to this significantly improved ligation efficiency, the method claimed in this invention is still able to target selected regions of the genome, as explained below.
[0187] On the one hand, the connector has the following structure: / 5'Phos / N1N2...N i -UMI-M1M2...M j -Blocker, where "5'Phos" represents the 5' phosphate group, "N1N2...N i "M1M2...M" represents the 5' sequence of the UMI sequence. j "" indicates the 3' sequence of the UMI sequence, and "blocker" indicates that the 3' end of the adapter is blocked to prevent it from being connected. i and j Both are integers, where iIt can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or greater than 30; and j The possible values are 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or greater than 50. In specific implementations, i It can be 2. In some implementations, N1N2...N i The dinucleotide sequence N1N2 at the 5' end can be GA (5' to 3'), GG (5' to 3'), AA (5' to 3'), or AG (5' to 3') to improve ligation efficiency.
[0188] On the one hand, M1M2...M j Part or all of the sequence is used in a later step to design a reverse complementary sequence, which serves as a primer to convert linked single-stranded polynucleotides into double-stranded polynucleotides, and / or for semi-targeted PCR to amplify the selected target sequence (the other primer in the primer pair is a target-specific primer). On one hand, M1M2...M j The sequence includes AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTG (SEQ ID NO: 732) or a portion thereof consisting of approximately 18 to 22 nucleotide residues.
[0189] On the other hand, “blockers” include carbon spacers, ddCTP, ddATP, ddTTP, ddGTP, hexanediol, triethylene glycol (TEG), and / or hexaethylene glycol, present in any suitable combination and order in the 5' to 3' orientation as one or more copies of one or more blocker groups.
[0190] On the one hand, the use of UMI helps to identify, select, and / or isolate error-free sequencing reads of target sequences, and allows for the selection of sequencing reads with high accuracy and high throughput. These validated error-free sequencing reads can be used in any technique requiring sequence fidelity, including constructing larger molecules with known sequences, polymorphism and / or mutation screening, massively parallel sequencing, and quantitative methods to eliminate methodological biases.
[0191] On the one hand, a unique molecular identifier (UMI) is associated with and uniquely identifies the construct comprising a single-stranded target polynucleotide and an adaptor. In other words, two single-stranded target polynucleotides with the same sequence can be ligated to two different adaptors at their respective UMI sequences; the resulting ligation products are distinct, and each ligation product (rather than target polynucleotides with the same sequence) is uniquely identified by the UMI. On the other hand, when single-stranded ligation products are converted to double-stranded polynucleotides and amplified, even with polymerases that provide very high fidelity, amplification errors can be introduced during repetitive replication. Therefore, even low error rates can have a significant impact, especially in the construction of large libraries. While massively parallel sequencing offers advantages in terms of cost and throughput, read accuracy can be limited by amplification and / or detection techniques.
[0192] By using UMI, the method of the present invention can identify error-free amplified products and / or sequencing reads and exclude amplified products and / or sequencing reads with technical errors from the analysis. Amplified products and / or sequencing reads with the same UMI can be identified as related (homologous), and therefore sequence differences between molecules with the same UMI can be identified as technical errors rather than true differences in the sequence (e.g., sequence differences between wild-type sequences and cancer-associated mutant sequences). In other words, since each single-stranded ligation product is uniquely identifiable by its UMI, all its progeny (due to amplification and / or sequencing) should have the same target sequence if no technical error is introduced. However, if an error (such as a single nucleotide insertion) is introduced into the target sequence during amplification and / or sequencing, some homologous (e.g., sharing the same UMI) amplified products and / or sequencing reads will have the insertion fragment, while other amplified products and / or sequencing reads will not. The exact ratio between products with and without the insertion will vary depending on when the error occurs during amplification and / or sequencing. Typically, when using very high-fidelity polymerases, the majority of products will be error-free. On the other hand, because homologous amplification products and / or sequencing reads can be identified, common sequences can be determined using data from multiple molecules, thereby achieving high accuracy in high-throughput sequencing.
[0193] On the one hand, UMIs are degenerate nucleic acid sequences, and the number of nucleotides in a UMI is designed such that the number of potential and actual sequences represented by the UMI sequence is greater than the total number of target single-stranded polynucleotides in the initial library. On the other hand, UMI sequence diversity (or “uniqueness” regarding each individual UMI sequence) can be provided by using a set of degenerate sequences randomly generated by synthesis with a mixture of all four bases at each position. Alternatively, different but predefined sets of sequences can be synthesized and ligated to the initial single-stranded polynucleotide library. The diversity of the UMI set must be high enough that molecules unrelated in origin are not mistakenly identified as related. On the other hand, the “unique” molecular identifier does not need to be absolutely unique and can be used for different target single-stranded polynucleotides, provided they are clearly different and not mistakenly identified as homologous molecules. The large number of UMI sequences that can be generated from the random assembly of nucleotides provides a high probability of uniquely identifying each individual ligation product. For example, if the UMI includes 12-mers synthesized with a mixture of A, C, G, and T at each position, there are 4 12 There are 4 possible sequences. If UMI comprises 20 polymers synthesized at each position using a mixture of A, C, G, and T, then there are 4 20 (approximately 10) 12 There are 100 possible sequences. The use of such random identifiers allows for a large library of single-stranded target polynucleotides that can be distinguished from one another.
[0194] In certain respects, UMI is a 5-mer, 6-mer, 7-mer, 8-mer, 9-mer, 10-mer, 11-mer, 12-mer, 13-mer, 14-mer, 15-mer, 16-mer, 17-mer, 18-mer, 19-mer, 20-mer, 21-mer, 22-mer, 23-mer, 24-mer, 25-mer, or even longer degenerate sequences. On one hand, the linker has the following structure: / 5'Phos / GANNNNNNNNNNNNAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTG / 3SpC3 / , where "NNNNNNNNNNNN" represents the 12-mer UMI sequence and "3SpC3" represents the 3' carbon spacer. The sequence of GANNNNNNNNNNNNAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTG is SEQ ID NO: 733.
[0195] The concentration of DNA can be artificially increased by adding condensing agents such as cobalt hexamine and biogenic polyamines such as spermidine, or by using congesting agents such as polyethylene glycol (PEG), which also increase the effective concentration of the enzyme. On the one hand, additives such as cobalt hexamine can generate only intermolecular reactions, producing linear linkage products rather than cyclic products. Therefore, in cases where the 5' end of the single-stranded target polynucleotide and the 3' end of the single-stranded adaptor may not be completely blocked to prevent linkage, additives such as cobalt hexamine can be used to enhance intermolecular reactions and further prevent cyclization of the single-stranded target polynucleotide and / or adaptor.
[0196] In some implementations, more than one configuration of the linker can be used in the same linkage reaction. For example, two configurations of the linker can be used: Configuration number 1: / 5'Phos / N1N2...N i -UMI1-M1M2...M j -Blocker 1, and Configuration number 2: / 5'Phos / P1P2...P k -UMI2-Q1Q2...Q l -Blocker 2.
[0197] N1N2...N i and P1P2...P k They can be the same or different; UMI1 and UMI2 can be the same or different; M1M2...M j and Q1Q2...Q l The components can be the same or different, and blocker 1 and blocker 2 can be the same or different. In one embodiment, UMI1 is different from UMI2 (e.g., UMI1 is a 12-mer degenerate sequence, while UMI2 is a 13-mer degenerate sequence), while other characteristics of the connector are the same. In another embodiment, N1N2...N i Unlike P1P2...P k (For example, one is AG and the other is GA), while the other characteristics of the connectors are the same. In yet another embodiment, M1M2...M j Unlike Q1, Q2...Q l In another embodiment, the blocking agent 1 and the blocking agent 2 are different, while the other characteristics of the connecting agent are the same.
[0198] Following the ligation reaction, the single-stranded ligation product is immediately converted to the double-stranded ligation product without any purification (e.g., separation of the ligation product from excess unligated adaptor molecules). Furthermore, neither the single-stranded target polynucleotide nor the adaptor needs to be captured on a solid support (e.g., via biotin-streptavidin-mediated bead binding) for subsequent conversion of the ligation product to double-stranded polynucleotides and / or amplification steps. Therefore, due to the purification or separation of the single-stranded ligation product, the method of the present invention avoids and / or reduces the already small loss of allele fractions of mutants in DNA samples (e.g., ctDNA). Conversely, the single-stranded ligation product remains in solution and is guided for primer extension.
[0199] Conversion of single-stranded polynucleotide libraries to double-stranded polynucleotide libraries On the one hand, such as Figure 2 As shown, after constructing a library containing single-stranded ligation products, the method may further include converting the library of linear single-stranded ligation products into a library of linear double-stranded ligation products. On one hand, the conversion uses primers or primer sets, each comprising sequences that are inversely complementary to and / or capable of hybridizing with the adaptor.
[0200] For connectors with the following structure: / 5'Phos / N1N2...N i -UMI-M1M2...M j - Blocking agents, primers may include those corresponding to M1M2...M j Reverse complementary and / or hybridizable sequences. In this embodiment, when the primer is coupled with a sequence having the structure ssDNA-N1N2...N i -UMI-M1M2...M j - During hybridization of the ligation product of the blocking agent, the primer extension reaction can convert ssDNA-N1N2...N i -UMI sequences (and optionally, M1M2...M j The sequence (in whole or in part) is converted into a double-stranded polynucleotide. In one specific embodiment, the reverse complementary primer includes the sequence shown in SEQ ID NO: 731, CACTCTTTCCCTACACGACGC (5' to 3').
[0201] In some implementations, the primers may not be M1M2...M j The complete inverse complement or a portion thereof; however, primers can be used with M1M2...M under stringent conditions. j (and thus the ssDNA linked to the adaptor) hybridizes.
[0202] In any of the foregoing embodiments, the method may further include amplifying and / or purifying a library of linear double-stranded ligation products. On one hand, the double-stranded ligation products are purified and sized to remove unbound adaptor molecules and / or unbound primers, and / or complexes formed between the adaptor and its reverse complementary primer. These fragments, which are typically shorter than the desired double-stranded ligation product, can be removed using any suitable method. For example, using a PCR purification column from Qiagen can help eliminate smaller fragments from the sample, and running the column-purified sample on a 2% certified low-range superagarose gel can help select the desired fragment size. Bead-based DNA purification, including the AMPure method, also helps remove smaller fragments. In some embodiments, the desired double-stranded ligation product size is from about 100 bp to about 600 bp, such as from about 100 bp to about 400 bp, from about 150 bp to about 200 bp, from about 200 bp to about 250 bp, and from about 250 bp to about 300 bp. In one implementation, dsDNA (>150 bp and <400 bp) is purified and collected, for example, by eluting beads suspended in Tri-EDTA buffer.
[0203] On the one hand, purification is bead-based. On the other hand, purification is size-selective, for example, purification steps selectively purify polynucleotides between about 50 nucleotides and about 1000 nucleotides in length, such as removing adaptors of about 40 nucleotides in length (and primer dimers and / or primer-adaptor duplexes of about 40 bp). Purification is also column-based, for example, using dsDNA or ssDNA purification columns, such as those from Zymo or Qiagen.
[0204] On the other hand, purification does not involve the use of specific binding pairs (such as biotin / streptavidin), one of which is linked to a linear double-stranded product and the other to a solid carrier (such as beads).
[0205] In any of the foregoing embodiments, the methods herein may further include, for example, amplifying a library of linear double-stranded ligated products by polymerase chain reaction (PCR) to obtain an amplified library of linear double-stranded ligated products including sequence information of the target sequence. This amplification may be unbiased amplification, for example, by ligating a universal adaptor pair to the ends of the double-stranded ligated products and amplifying all labeled double-stranded ligated products using universal primer pairs. In other embodiments, semi-targeted amplification may be performed instead of unbiased amplification or in addition to unbiased amplification. Semi-targeted amplification may be performed before or after unbiased amplification.
[0206] Semi-targeted amplification of double-stranded polynucleotide libraries On the one hand, such as Figure 2As shown, semi-targeted amplification of the double-stranded ligation product library includes primers comprising sequences that are inversely complementary to and / or hybridize with the adaptor, and primers that hybridize with the target sequence (e.g., the targets listed in Table 2) or primers that hybridize with the same target sequence or multiple target sequences.
[0207] For connectors with the following structure: / 5'Phos / N1N2...N i -UMI-M1M2...M j - Blocking agents, primers may include those corresponding to M1M2...M j The reverse complementary and / or hybridizable sequences. Thus, when a primer hybridizes to one strand of the dsDNA and a target-specific primer hybridizes to the other strand of the dsDNA, the PCR product will include the target sequence and N1N2...N i -UMI sequences (and optionally, M1M2...M j (All or part of the sequence). In one specific embodiment, the reverse complementary primer includes the sequence shown in SEQ ID NO: 731, CACTCTTTCCCTACACGACGC (5' to 3').
[0208] On the one hand, multiple target-specific primers can be used, each containing a sequence specific to the same or different target sequences. In other words, primers can have the same or different target sequences. In some embodiments, the target-specific primer pool includes about 5, about 10, about 25, about 50, about 100, about 150, about 200, about 250, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, or more than about 1000 different primers, such as about 10 4 Approximately 10 5 Approximately 10 6 One or more primers. In other embodiments, the pool includes different primers ranging from about 20 to about 60, from about 60 to about 100, from about 100 to about 140, from about 140 to about 180, from about 180 to about 220, from about 220 to about 260, from about 260 to about 300, from about 300 to about 350, or from about 350 to about 400. On one hand, the target-specific primer pool is used with a common reverse complementary primer, wherein the common reverse complementary primer forms a primer pair with each individual target-specific primer in the pool to amplify the target sequence in and / or between the primers in a semi-targeted manner. Therefore, in this respect, the semi-targeted amplification is not whole-genome amplification.
[0209] Because ctDNA is randomly fragmented, the primer positions of target-specific primers can be important. For example, if the primer binding site crosses the breakpoint, it may lead to lower transformation rates. A larger pool of target-specific primers and / or the use of multiple partially overlapping primers for the same target sequence can address this issue.
[0210] On the one hand, the sequence information of the target sequence can include mutations, single nucleotide polymorphisms (SNPs), copy number variations (CNVs), or epigenetic changes. On the other hand, mutations include point mutations, insertions, deletions, inversions, truncations, fusions, amplifications, or any combination thereof.
[0211] In some implementations, the amplified library of the linear double-stranded ligation product can be a library other than a whole-genome library, such as a semi-targeted genome library.
[0212] In some embodiments, the method may further include purifying the amplified library of linear double-stranded ligation products. Smaller fragments, including primer dimers, can be removed using any suitable method. For example, using a PCR purification column from Qiager can help eliminate smaller fragments from the sample, and running the column-purified sample on a 2% certified low-range superagarose gel can help select the desired fragment size. Bead-based DNA purification, including the AMPure method, also helps remove smaller fragments. In some embodiments, the amplified product size is from about 100 bp to about 600 bp, such as about 100 bp to about 400 bp, about 150 bp to about 200 bp, about 200 bp to about 250 bp, and about 250 bp to about 300 bp. In one embodiment, dsDNA (> 150 bp and < 400 bp) is purified and collected, for example, by eluting beads suspended in Tri-EDTA buffer.
[0213] On the one hand, purification is bead-based. On the other hand, purification is size-selective, for example, purification steps selectively purify polynucleotides longer than about 150 nucleotides. Purification also does not involve the use of specific binding pairs (such as biotin / streptavidin), one ligated to a linear double-stranded product and the other to a solid carrier (such as beads). Purification is also column-based, for example, using dsDNA or ssDNA purification columns, such as those from Zymo or Qiagen.
[0214] Sequence library construction and sequencing read analysis On one hand, the method further includes sequencing the purified amplified library of the linear double-stranded ligation products. On the other hand, the sequencing step includes ligating sequencing adaptors and / or sample-specific barcodes to each linear double-stranded ligation product. In one particular aspect, the ligation step is performed using polymerase chain reaction (PCR).
[0215] Figure 3 An exemplary configuration of a construct including a target molecule for sequencing is shown. For Illumina sequencing, these constructs have flow cell binding sites P5 and P7 at each end, which allow library fragments to be linked to the flow cell surface. The P5 and P7 regions of the single-stranded library fragment are annealed to their complementary oligonucleotides on the flow cell surface. The flow cell oligonucleotides act as primers, and strands complementary to the library fragments are synthesized. The original strands are then washed away, leaving copies of the fragments covalently bonded to the flow cell surface in a mixed orientation. Copies of each fragment are then generated by bridging amplification, producing clusters. The P5 regions are then cleaved, producing clusters containing only fragments linked by the P7 regions. This ensures that all copies are sequenced in the same orientation. Sequencing primers are annealed to the P5 ends of the fragments, and the sequencing-by-synthesis process begins. Indexing reads are performed while the sample is barcoded. When read 1 is complete, all content from read 1 is removed and index primers are added, which anneal at the P7 ends of the fragments, and the barcodes are sequenced. Then, everything is stripped from the template, and clusters are formed by bridging amplification, as in read 1. This leaves copies of the fragments covalently bonded to the flow cell surface in a mixed orientation. This time, P7, instead of P5, is cut, producing clusters that include only fragments connected by the P5 region. This ensures that all copies are sequenced in the same direction (opposite to the direction of read 1). Sequencing primers are annealed to the P7 region, and the other end of the template is sequenced.
[0216] Next-generation sequencing platforms, such as MiSeq (Immena, San Diego, California), can be used for highly multiplexed assay readouts. A variety of statistical tools can be used to analyze assay results, such as proportion tests and multiple comparison correction based on false discovery rates (see Benjamini and Hochberg, 1995, *Journal of the Royal Statistical Society: Series B (Methodology)*). Journal of the Royal Statistical Society Series B (Methodological) 57, 289-300) and Bonferroni correction for multiple tests. Additionally, methods developed for analyzing differential expression from RNA-Seq data can be used to reduce the variance per target sequence and increase the overall power in the analysis. See Smyth, 2004, Stat. Appl. Genet. Mol. Biol. 3, Item 3.
[0217] In summary, in some embodiments, the conversion rate of the method of the present invention is at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95%. On the one hand, conversion rate is the percentage of target single-stranded polynucleotides in the initial library that generate sequencing reads.
[0218] In any of the foregoing embodiments, the method can be used for the diagnosis and / or prognosis of a subject's disease or symptom, predicting a subject's response to treatment, identifying pharmacogenetic markers of the disease / symptom or treatment, and / or screening the genetic information of a population. In one aspect, the disease or symptom is cancer or tumor formation, and the treatment is a cancer or tumor treatment.
[0219] Mutated DNA molecules offer a unique advantage over cancer-associated biomarkers because they are highly specific. Although mutations occur at a low rate (approximately 10^6) in individual normal cells... -9 Up to 10 -10 Mutations occur at a rate of 1 bp / generation, but these mutations represent such a small fraction of the total normal DNA that they are orders of magnitude lower than the detection limits of some existing techniques. Several studies have shown that mutated DNA can be detected in the stool, urine, and blood of CRC patients (Osborn and Ahlquist, Stool screening for colorectal cancer: molecular approaches, Gastroenterology). Gastroenterology (2005;128:192-206).
[0220] Based on the sequencing results presented in this paper, circulating tumor DNA (CMD) can be detected in patients, enabling cancer diagnosis and prediction of tumor recurrence. These predictions can then guide treatment and monitoring decisions. For example, CMD indicating future recurrence may prompt additional or more aggressive therapies, as well as additional or more sophisticated imaging and monitoring. Circulating DNA refers to DNA that is ectopic within the tumor.
[0221] Samples that can be used to monitor ctDNA include blood and stool. Blood samples can be, for example, a portion of blood, such as serum or plasma. Similarly, stool can be graded to purify DNA from other components. Tumor samples are used to identify somatic mutations in tumors that can be used as markers for tumors in other locations in the body. Thus, as an example, specific somatic mutations in tumors can be identified by any standard method known in the art. Typical methods include direct sequencing of tumor DNA, using allele-specific probes, allele-specific amplification, primer extension, etc. Once a somatic mutation is identified, it can be used in other compartments of the body to distinguish tumor-derived DNA from DNA originating from other cells in the body. The somatic mutation is confirmed by determining that it does not occur in normal tissues of the same patient's body. The types of tumors that can be diagnosed and / or monitored in this way are virtually unlimited. Any tumor that has shed cells and / or DNA into blood, stool, or other bodily fluids can be used. In addition to colorectal tumors, such tumors include those of the breast, lung, kidney, liver, pancreas, stomach, brain, head and neck, lymph nodes, ovaries, uterus, bones, blood, etc.
[0222] On the one hand, the methods disclosed in this paper can be used to construct libraries for sequencing and / or determining the epigenetic status of one or more regions of a target sequence. DNA methylation is one of the earliest discovered epigenetic markers. Epigenetics is the study of changes in gene expression or cellular phenotype caused by mechanisms other than underlying DNA sequence changes. Methylation primarily involves adding a methyl group to the carbon-5 position of a cytosine residue in a dinucleotide CpG and is associated with repression or inhibition of transcriptional activity.
[0223] Bisulfite conversion is the treatment of DNA with a bisulfite reagent to determine its methylation pattern. Treatment of DNA with bisulfite converts cytosine residues to uracil, but 5-methylcytosine residues are unaffected. Therefore, bisulfite treatment introduces specific changes in the DNA sequence that depend on the methylation state of individual cytosine residues. Various analyses can be performed on the altered sequence to retrieve this information, for example, to distinguish single nucleotide polymorphisms (SNPs) resulting from bisulfite conversion. U.S. Patent Nos. 7,620,386, 9,365,902, and U.S. Patent Application Publication 2006 / 0134643 (all of which are incorporated herein by reference) illustrate methods known to those skilled in the art for detecting sequences altered due to bisulfite conversion.
[0224] As discussed above, one consequence of bisulfite conversion is the disruption of the original target's double-stranded conformation due to the loss of sequence complementarity. While this may pose problems for conventional methods used to construct double-stranded libraries, the method of this invention is uniquely suited for constructing single-stranded libraries from bisulfite-converted samples for sequencing analysis.
[0225] On the other hand, the method of the present invention can be used in combination with methods for determining methylation status, such as those described in U.S. Provisional Application No. 62 / 487,422 and US 2020 / 0048697 A1, filed April 19, 2017, entitled “Compositions and Methods for Detection of Genomic Variance and DNA Methylation Status,” which are incorporated herein by reference in their entirety for all purposes. In one embodiment, the sample is contacted with a methylation-sensitive restriction enzyme (MSRE) prior to a dephosphorylation and / or denaturation step, and then a single-stranded library is constructed by ligation as disclosed herein to analyze the methylation profile.
[0226] Other exemplary embodiments In any of the foregoing embodiments, the ssDNA ligase may be a genus of Thermophyton (Bacteria spp.) Thermus Phage RNA ligases, such as phage TS2126 RNA ligases (e.g., CircLigase™ and CircLigase II™), or archaebacterium RNA ligases, such as thermoautotrophic methanobacteria (… Methanobacterium thermoautotrophicum 5' RNA ligase 1. In other respects, the ssDNA ligase is an RNA ligase, such as a T4 RNA ligase, for example, T4 RNA ligase I, such as New England Biosciences, M0204S, T4 RNA ligase 2, such as New England Biosciences, M0239S, a truncated form of T4 RNA ligase 2, such as New England Biosciences, M0242S, a truncated form of T4 RNA ligase 2 KQ, such as M0373S, or a truncated form of T4 RNA ligase 2 K227Q, such as New England Biosciences, M0351S. In any of the foregoing embodiments, the kit may also include a heat-stable 5' App DNA / RNA ligase, such as New England Biosciences, M0319S, or a T4 DNA ligase, such as New England Biosciences, M0202S.
[0227] In some embodiments, the method of the present invention includes ligating a set of adaptors to a library of single-stranded polynucleotides using a single-stranded DNA (ssDNA) ligase. Any suitable ssDNA ligase can be used, including the ssDNA ligases disclosed herein. Adaptors can be used at any suitable level or concentration, for example, from about 1 µM to about 100 µM, such as about 1 µM, 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, 60 µM, 70 µM, 80 µM, 90 µM, or 100 µM or any subrange thereof. Adaptors can comprise any suitable sequence or base or begin with any suitable sequence or base. For example, the adaptor sequence can begin with all 2 bp base combinations.
[0228] In some embodiments, the linkage reaction can be carried out in the presence of a congesting agent. Congesting agents include polyethylene glycol (PEG), such as PEG 4000, PEG 6000, or PEG 8000, dextran, and / or Ficoll. Congesting agents, such as PEG, can be used at any suitable level or concentration. For example, congestants (such as PEG) can be used at about 0% (w / v) to about 25% (w / v), for example, at levels or concentrations of about 0% (w / v), 1% (w / v), 2% (w / v), 3% (w / v), 4% (w / v), 5% (w / v), 6% (w / v), 7% (w / v), 8% (w / v), 9% (w / v), 10% (w / v), 11% (w / v), 12% (w / v), 13% (w / v), 14% (w / v), 15% (w / v), 16% (w / v), 17% (w / v), 18% (w / v), 19% (w / v), 20% (w / v), 21% (w / v), 22% (w / v), 23% (w / v), 24% (w / v), or 25% (w / v) or any subrange thereof.
[0229] In some implementations, the linkage reaction can proceed for any suitable duration. For example, the linkage reaction can proceed for approximately 2 hours to approximately 16% of the time, such as approximately 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, or 16 hours or any subrange thereof.
[0230] In some embodiments, the ssDNA ligase in the ligation reaction can be used in any suitable volume. For example, the ssDNA ligase in the ligation reaction can be used in volumes of about 0.5 µl to about 2 µl%, such as about 0.5 µl, 0.6 µl, 0.7 µl, 0.8 µl, 0.9 µl, 1 µl, 1.1 µl, 1.2 µl, 1.3 µl, 1.4 µl, 1.5 µl, 1.6 µl, 1.7 µl, 1.8 µl, 1.9 µl, or 2 µl or any subrange thereof.
[0231] In some embodiments, the linkage reaction can be carried out in the presence of a linkage enhancer such as betaine. The linkage enhancer, such as betaine, can be used in any suitable volume, for example, from about 0 µl to about 1 µl, such as about 0 µl, 0.1 µl, 0.2 µl, 0.3 µl, 0.4 µl, 0.5 µl, 0.6 µl, 0.7 µl, 0.8 µl, 0.9 µl, 1 µl, or any subrange thereof.
[0232] In some embodiments, the ligation reaction can be performed using T4 RNA ligase I, such as T4 RNA ligase I, MO204S from New England Biosciences, in the following exemplary reaction mixture (20 µl): 1 × reaction buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM DTT), 25% (wt / vol) PEG 8000, 1 mM hexamine cobalt chloride (optional), 1 µl (10 units) of T4 RNA ligase, and 1 mM ATP. The reaction can be incubated at 25°C for 16 hours. The reaction can be terminated by adding 40 µl of 10 mM Tris-HCl pH 8.0 and 2.5 mM EDTA.
[0233] In some embodiments, the ligation reaction can be carried out using a thermostable 5' App DNA / RNA ligase, such as the thermostable 5' App DNA / RNA ligase M0319S from New England Biosciences, in the following exemplary reaction mixture (20 µl): 20 pmol of ssDNA / RNA substrate (1 pmol / µl), 40 pmol of 5' App DNA oligonucleotide (2 pmol / µl), 10X NEBuffer 1 (2 µl), 50 mM MnCl2 (for ssDNA ligation only) (2 µl), thermostable 5' App DNA / RNA ligase (2 µl (40 pmol)), and nuclease-free water (up to 20 µl). The reaction can be incubated at 65°C for 1 hour. The reaction can be terminated by heating at 90°C for 3 minutes.
[0234] In some embodiments, the ligation reaction can be performed using T4 RNA ligase 2, such as T4 RNA ligase 2, M0239S from New England Biosciences, in the following exemplary reaction mixture (20 µl): T4 RNA ligase buffer (2 µl), enzyme (1 µl), PEG (10 µl), DNA (1 µl), adaptor (2 µl), and water (4 µl). The reaction can be incubated at 25 °C for 16 hours. The reaction can be terminated by heating at 65 °C for 20 minutes.
[0235] In some embodiments, the ligation reaction can be performed using a truncated form of T4 RNA ligase 2, such as T4 RNA ligase 2 truncated form M0242S from New England Biosciences, in the following exemplary reaction mixture (20 µl): T4 RNA ligase buffer (2 µl), enzyme (1 µl), PEG (10 µl), DNA (1 µl), adaptor (2 µl), and water (4 µl). The reaction can be incubated at 25 °C for 16 hours. The reaction can be terminated by heating at 65 °C for 20 minutes.
[0236] In some embodiments, the ligation reaction can be performed using a truncated form of T4 RNA ligase 2, K227Q, such as T4 RNA ligase 2 truncated form K227Q, M0351S from New England Biosciences, in the following exemplary reaction mixture (20 µl): T4 RNA ligase buffer (2 µl), enzyme (1 µl), PEG (10 µl), DNA (1 µl), adenylate adaptor (0.72 µl), and water (5.28 µl). The reaction can be incubated at 25 °C for 16 hours. The reaction can be terminated by heating at 65 °C for 20 minutes.
[0237] In some embodiments, the ligation reaction can be performed using T4 RNA ligase 2 truncated variant KQ, such as T4 RNA ligase 2 truncated variant KQ, M0373S from New England Biosciences, in the following exemplary reaction mixture (20 µl): T4 RNA ligase buffer (2 µl), enzyme (1 µl), PEG (10 µl), DNA (1 µl), adenylate adaptor (0.72 µl), and water (5.28 µl). The reaction can be incubated at 25 °C for 16 hours. The reaction can be terminated by heating at 65 °C for 20 minutes.
[0238] In some embodiments, the ligation reaction can be performed using T4 DNA ligase, such as T4 DNA ligase M0202S from New England Biosciences, in the following exemplary reaction mixture (20 µl): T4 RNA ligase buffer (2 µl), enzyme (1 µl), PEG (10 µl), DNA (1 µl), adenylate adaptor (0.72 µl), and water (5.28 µl). The reaction can be incubated at 16 °C for 16 hours. The reaction can be terminated by heating at 65 °C for 10 minutes.
[0239] The second-strand synthesis step can be performed using any suitable enzyme. For example, the second-strand synthesis step can be performed using Bst polymerase, such as New England Biosciences M0275S, or Klenow fragment (3'->5' exo-), such as New England Biosciences M0212S.
[0240] In some embodiments, the second-strand synthesis step can be performed using Bst polymerase, such as New England Biosciences, M0275S, in the following exemplary reaction mixture (10 µl): water (1.5 µl), primers (0.5 µl), dNTPs (1 µl), ThermoPol reaction buffer (5 µl), and Bst (2 µl). The reaction can be incubated at 62 °C for 2 min and at 65 °C for 30 min. After the reaction, the double-stranded DNA molecules are further purified.
[0241] In some embodiments, the second-strand synthesis step can use the Klenow fragment (3'->5' exo-), such as New England Biosciences, M0212S, in the following exemplary reaction mixture (10 µl): water (0.5 µl), primers (0.5 µl), dNTPs (1 µl), NEB buffer (2 µl), and exo- (3 µl). The reaction can be incubated at 37°C for 5 min and at 75°C for 20 min. After the reaction, the double-stranded DNA molecules are further purified.
[0242] Double-stranded DNA can be purified after second-strand synthesis but before first or semi-targeted PCR. Any suitable technique or procedure can be used to purify double-stranded DNA. For example, double-stranded DNA can be purified using any of the following kits: Zymo Cleaner and Concentrator, Zymo Research, D4103; Qiaquick, Qiagen, 28104; Zymoss DNA Purification Kit, Zymo Research, D7010; Zymo Oligonucleotide Purification Kit, Zymo Research, D4060; and AmpureXP Beads, Beckman Coulter, A63882: 1.2x–4x bead ratio.
[0243] First- or semi-targeted PCR can be performed using any suitable enzymes or reaction conditions. For example, polynucleotides or DNA strands can be annealed at approximately 52°C to approximately 72°C, such as at approximately 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, or 72°C or any subrange thereof. First- or semi-targeted PCR can be performed in any suitable number of cycles. For example, first- or semi-targeted PCR can be performed for 10-40 cycles, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 cycles. Primer pools can be used at any suitable concentration. For example, primer cells can be used at concentrations of about 5 nm to about 200 nm, such as about 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, 150 nm, 160 nm, 170 nm, 180 nm, 190 nm or 200 nm or any subrange thereof.
[0244] First- or semi-targeted PCR can be performed using any suitable temperature cycling conditions. For example, first- or semi-targeted PCR can be performed using any of the following cycling conditions: 95°C for 3 minutes, (95°C for 15 seconds, 62°C for 30 seconds, 72°C for 90 seconds) x3 or x5; or (95°C for 15 seconds, 72°C for 90 seconds) x23 or x21, 72°C for 1 minute, 4°C for forever.
[0245] In some embodiments, the first or semi-targeted PCR can be performed using KAPA SYBR FAST, such as KAPA biosciences, KK4600, in the following exemplary reaction mixture (50 µl): DNA (2 µl), KAPASYBR (25 µl), primer pool (26 nM each) (10 µl), primers (100 uM) (0.4 µl), and water (12.6 µl). The first or semi-targeted PCR can be performed using any of the following cycling conditions: 95°C for 30 seconds, (95°C for 10 seconds, 50-56°C for 45 seconds, 72°C for 35 seconds) x 40.
[0246] In some implementations, the first or semi-targeted PCR can be performed using KAPA HiFi, such as KAPA Biosciences, KK2601, in the following exemplary reaction mixture (50 µl): DNA (15 µl), KAPA HiFi (25 µl), primer pool (26 nM each) (10 µl), and primers (100 uM) (0.4 µl). The first or semi-targeted PCR can be performed using any of the following cycling conditions: 95°C for 3 minutes, (98°C for 20 seconds, 53-54°C for 15 seconds, 72°C for 35 seconds) x 15, 72°C for 2 minutes, 4°C for forever.
[0247] Bisulfite conversion can be performed using any suitable technique, procedure, or reagent. In some embodiments, bisulfite conversion can be performed using any of the following kits and procedures provided in the kits: EpiMark Bisulfite Conversion Kit, New England Biosciences, E3318S; EZ DNA Methylation Kit, Zymo Research, D5001; MethylCode Bisulfite Conversion Kit, Thermo Fisher Scientific, MECOV50; EZ DNA Methylation Gold Kit, Zymo Research, D5005; EZ DNA Methylation Direct Kit, Zymo Research, D5020; EZ DNA Methylation Lightning Kit, Zymo Research, D5030T; EpiJET Bisulfite Conversion Kit, Thermo Fisher Scientific, K1461; or EpiTect Bisulfite Kit, Qiagen, 59104.
[0248] In some implementations, DNA molecules can be prepared using the procedure shown in Example 3, including steps for constructing single-stranded polynucleotides, converting a single-stranded polynucleotide library into a double-stranded polynucleotide library, semi-targeted amplification of the double-stranded polynucleotide library, and constructing a sequence library. The methylation status of such DNA molecules can be further analyzed using any suitable method or procedure.
[0249] In some respects, the invention is further illustrated in the following exemplary embodiments.
[0250] 1. An in vitro method for classifying samples, the method comprising: a) Assess the methylation status of one or more tissue-specific or organ-specific target polynucleotides from a subject in vitro, said sample containing cellular free target polynucleotides from the subject; and b) To classify the sample into a category based on the methylation status of one or more tissue-specific or organ-specific target polynucleotides in the sample obtained in a).
[0251] 2. The method according to embodiment 1, wherein step 1) includes in vitro assessment of the methylation status of a tissue-specific or organ-specific target polynucleotide of a subject in a sample, said sample containing cellular free target polynucleotides from said subject.
[0252] 3. The method according to embodiment 1, wherein step 1) includes in vitro assessment of the methylation status of two or more tissue-specific or organ-specific target polynucleotides of a subject in a sample, the sample containing cellular free target polynucleotides from the subject.
[0253] 4. The method according to any one of embodiments 1 to 3, wherein step 1) comprises in vitro assessment of the methylation status of one or more tissue-specific target polynucleotides of the subject in a sample, said sample comprising cellular free target polynucleotides from said subject. 5. The method according to embodiment 4, which is used to assess tissue damage or toxicity in the subject.
[0254] 6. The method according to embodiment 5, wherein the tissue is selected from the group consisting of connective tissue, epithelial tissue, muscle tissue, and nerve tissue.
[0255] 7. The method according to any one of embodiments 1 to 3, wherein step 1) includes in vitro assessment of the methylation status of one or more organ-specific target polynucleotides of a subject in a sample, said sample containing cellular free target polynucleotides from said subject.
[0256] 8. The method according to embodiment 7, which is used to assess organ damage or toxicity in the subject.
[0257] 9. The method according to embodiment 8, wherein the organ is an organ of a system selected from the group consisting of: the cardiovascular system, such as the lungs, heart, blood, and blood vessels; the digestive system, such as the salivary glands, esophagus, stomach, liver, gallbladder, pancreas, intestine, colon, mesentery, rectum, and anus; and the endocrine system, such as endocrine glands, such as the hypothalamus, pituitary gland, pineal gland or pineal gland, thyroid gland, parathyroid gland, and adrenal gland (i.e., adrenal gland). The excretory system, such as the kidneys, ureters, bladder, and urethra; the lymphatic system, such as lymph nodes and lymphatic vessels that transport lymph, including the immune system: defending against pathogenic factors with white blood cells, tonsils, adenoids, thymus, and spleen; the exodermal system, such as the skin, hair, and nails of mammals; the muscular system, such as muscles; the nervous system, such as the brain, spinal cord, and nerves; the reproductive system, such as sex organs like the ovaries, fallopian tubes, uterus, vulva, vagina, testes, vas deferens, seminal vesicles, prostate, and penis; the respiratory system, such as the pharynx, larynx, trachea, bronchi, lungs, and diaphragm; and the skeletal system, such as bones, cartilage, ligaments, and tendons.
[0258] 10. The method according to embodiment 8, wherein the organ is selected from the group consisting of: liver, kidney, heart, stomach, lung, testis, small intestine, colon, and gastrocnemius muscle.
[0259] 11. The method according to any one of embodiments 5 to 10, wherein the tissue or organ damage or toxicity of the subject is caused by treatment of the subject with a substance.
[0260] 12. The method according to embodiment 11, wherein the substance is a drug or a drug candidate.
[0261] 13. The method according to embodiment 12, wherein the drug or drug candidate is a chemical or small molecule drug or drug candidate.
[0262] 14. The method according to embodiment 12, wherein the drug or drug candidate is a biomolecular drug or drug candidate.
[0263] 15. The method according to embodiment 14, wherein the biomolecular drug or drug candidate is a polypeptide, a polynucleotide, or a complex thereof.
[0264] 16. The method according to any one of embodiments 12 to 15, wherein the drug or drug candidate is a conjugated drug or drug candidate.
[0265] 17. The method according to any one of embodiments 1 to 16, wherein step b) comprises generating a methylation status score using a computer algorithm based on the assessed methylation status of the one or more tissue-specific target polynucleotides, and classifying the sample into a category based on the methylation status score.
[0266] 18. The method according to any one of embodiments 1 to 17, wherein the sample is a blood sample, a urine sample, a cerebrospinal fluid sample, a pleural fluid sample, and a saliva sample.
[0267] 19. The method according to embodiment 18, wherein the blood sample is a serum sample, a plasma sample, or any combination thereof.
[0268] 20. The method according to any one of embodiments 1 to 19, wherein the subject is a mammal.
[0269] 21. The method according to embodiment 20, wherein the mammal is a non-human mammal, such as a pet, farm animal, companion animal, or laboratory animal.
[0270] 22. The method according to embodiment 20, wherein the mammal is a human.
[0271] 23. The method according to any one of embodiments 1 to 22, comprising evaluating the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides.
[0272] 24. The method according to any one of embodiments 1 to 23, wherein the methylation status of the tissue-specific or organ-specific target polynucleotide is assessed using a probe or primer configured to hybridize with each target polynucleotide.
[0273] 25. The method according to any one of embodiments 1 to 24, wherein the methylation status of the tissue-specific or organ-specific target polynucleotide is assessed using a single probe or primer configured to hybridize with the target polynucleotide.
[0274] 26. The method according to any one of embodiments 1 to 24, wherein the methylation status of the tissue-specific or organ-specific target polynucleotide is evaluated using a plurality of probes or primers configured to hybridize with the tissue-specific or organ-specific target polynucleotide.
[0275] 27. The method according to any one of embodiments 1 to 26, further comprising using a common primer to amplify each of the tissue-specific or organ-specific target polynucleotides whose methylation status is to be evaluated.
[0276] 28. The method according to embodiment 27, wherein the common primer comprises the sequence shown in SEQ ID NO: 731 (CACTCTTTCCCTACACGACGC), a sequence complementary to or substantially complementary to it, or is substantially composed of or constitutes thereof.
[0277] 29. The method according to any one of embodiments 1 to 28, further comprising isolating the tissue-specific or organ-specific target polynucleotide from a sample (e.g., a blood sample).
[0278] 30. The method according to any one of embodiments 1 to 29, further comprising preparing a library of the tissue-specific or organ-specific target polynucleotides.
[0279] 31. The method according to embodiment 30, wherein the library of tissue-specific or organ-specific target polynucleotides is prepared using an enzyme (e.g., a ligase or a single-stranded DNA (ssDNA) ligase).
[0280] 32. The method according to embodiment 31, wherein the ssDNA ligase is T4 RNA ligase I, a thermostable 5' App DNA / RNA ligase, T4 RNA ligase 2, a truncated T4 RNA ligase 2, such as a truncated form of T4 RNA ligase 2, a truncated form of T4 RNA ligase 2 K227Q, a truncated form of T4 RNA ligase 2 KQ, or a T4 DNA ligase, a Thermus phage RNA ligase, such as phage TS2126 RNA ligase (e.g., CircLigase™ and CircLigase II™), or an Archaebacterium RNA ligase, such as Methanobacterium thermoautotrophicum RNA ligase 1.
[0281] 33. The method according to any one of embodiments 1 to 32 further includes amplifying the tissue-specific or organ-specific target polynucleotide.
[0282] 34. The method according to embodiment 33, wherein the tissue-specific or organ-specific target polynucleotide is amplified using a procedure selected from the group consisting of: polymerase chain reaction (PCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA), ligase chain reaction (LCR), nucleic acid sequence-based amplification (NASBA), primer extension, rolling circle amplification (RCA), self-sustaining sequence replication (3SR), and loop-mediated isothermal amplification (LAMP).
[0283] 35. The method according to any one of embodiments 1 to 34, further comprising purifying the tissue-specific or organ-specific target polynucleotide, a library of the tissue-specific or organ-specific target polynucleotide, amplified tissue-specific or organ-specific target polynucleotide, or a library of the amplified tissue-specific or organ-specific target polynucleotide.
[0284] 36. The method according to any one of embodiments 1 to 35, wherein the methylation status of the tissue-specific or organ-specific target polynucleotide is assessed using mass spectrometry, methylation-specific PCR (MSP), methylation-sensitive sequencing (e.g., bisulfite sequencing), HpaII microfragment enrichment assay by ligation-mediated PCR (HELP assay), Glal hydrolysis and ligation adaptor-dependent PCR assay (GLAD-PCR assay), restriction marker genomic scanning (RLGS), methylated DNA immunoprecipitation (MeDIP or mDIP), pyrosequencing, molecular fragmentation assay for DNA adenine methyltransferase activity, methyl-sensitive Southern blotting, or high-resolution melting (HRM) analysis.
[0285] 37. The method according to embodiment 36, wherein assessing the methylation status of the tissue-specific or organ-specific target polynucleotide includes using a chemical agent, such as bisulfite or sodium bisulfite.
[0286] 38. The method according to embodiment 36, wherein assessing the methylation status of the tissue-specific or organ-specific target polynucleotide includes using a biological reagent, such as a peptide or an enzyme.
[0287] 39. The method according to embodiment 38, wherein the enzyme is a methylation-sensitive restriction enzyme (MSRE).
[0288] 40. The method according to embodiment 39, wherein when unmethylated, the MSRE is selectively cleaved at residues.
[0289] 41. The method according to embodiment 39, wherein when methylated, the MSRE selectively cleaves at the residue.
[0290] 42. The method according to embodiments 39 to 41, wherein the MSRE is selected from the group consisting of: HpaII, SalI, SalI-HF®, ScrFI, BbeI, NotI, SmaI, XmaI, MboI, BstBI, ClaI, MluI, NaeI, NarI, PvuI, SacII, HhaI, and combinations thereof.
[0291] 43. The method according to embodiment 38, wherein the enzyme is a polynucleotide polymerase.
[0292] 44. The method according to embodiment 43, wherein the polynucleotide polymerase is configured for PCR.
[0293] 45. The method according to embodiment 44, wherein the polynucleotide polymerase is a DNA polymerase, such as a DNA polymerase without 3' to 5' exonuclease activity.
[0294] 46. The method according to any one of embodiments 1 to 45, wherein the methylation state of the tissue-specific or organ-specific target polynucleotide is assessed using methylation-sensitive sequencing (e.g., bisulfite sequencing).
[0295] 47. The method according to embodiment 46, wherein the methylation-sensitive sequencing is performed in a manner selected from the group consisting of: Maxam-Gilbert sequencing, chain termination sequencing, shotgun sequencing, bridge PCR, single-molecule real-time sequencing, ion semiconductor (ion torrent sequencing) sequencing, synthesis sequencing, ligation sequencing (SOLiD sequencing), chain termination (Sanger sequencing) sequencing, massively parallel signature sequencing (MPSS), polymerase cloning sequencing, 454 pyrosequencing, Illumina (Solexa) sequencing, DNA nanosphere sequencing, heliscope single-molecule sequencing, single-molecule real-time (SMRT) sequencing, nanopore DNA sequencing, tunneling current DNA sequencing, hybridization sequencing, mass spectrometry sequencing, microfluidic Sanger sequencing, microscopy-based techniques, RNAP sequencing, and in vitro viral high-throughput sequencing.
[0296] 48. The method according to embodiment 46 or 47 further includes, prior to the methylation-sensitive sequencing (e.g., bisulfite sequencing), obtaining a library of linear single-stranded ligation products, each linear single-stranded ligation product comprising a linear single-stranded target polynucleotide linked to an adaptor, the adaptor comprising a unique molecular identifier (UMI) sequence that tags the single-stranded target polynucleotide linked to the adaptor.
[0297] 49. The method according to embodiment 48, wherein the sequencing reads from the tissue-specific or organ-specific target polynucleotides are first adapted to remove any adaptor sequences originating from the library construction process, thereby obtaining adapted sequencing reads.
[0298] 50. The method according to embodiment 49, wherein the pruned sequencing reads are mapped to a reference genome, such as a human reference genome, using an alignment procedure to obtain an aligned read file.
[0299] 51. The method according to any one of embodiments 1 to 50, wherein the methylation status of each of the tissue-specific or organ-specific target polynucleotides is evaluated.
[0300] 52. The method according to embodiment 51, wherein the methylation status of each of the tissue-specific or organ-specific target polynucleotides is assessed to obtain a methylation metric, for example, in the form of average methylation frequency, methylated haplotype load, unmethylated haplotype load, percentage of inconsistent reads, or a combination thereof.
[0301] 53. The method according to embodiment 52, wherein the methylation status of a sample (e.g., a blood sample) is assessed using methylation measures from each of the tissue-specific or organ-specific target polynucleotides.
[0302] 54. The method according to embodiment 53, wherein a methylation measure of each of the tissue-specific or organ-specific target polynucleotides is compared with a threshold or reference value to assess the methylation status of a sample (e.g., a blood sample).
[0303] 55. The method according to embodiment 53 or 54, wherein a numerical methylation matrix is calculated using methylation measures from each of the tissue-specific or organ-specific target polynucleotides to assess the methylation status of a sample (e.g., a blood sample).
[0304] 56. The method according to embodiment 55, wherein the numerical methylation matrix from a sample (e.g., a blood sample) comprises a single numerical value or value.
[0305] 57. The method according to embodiment 55, wherein the numerical methylation matrix from a sample (e.g., a blood sample) comprises a plurality of numerical values or values.
[0306] 58. The method according to any one of embodiments 55 to 57, wherein the numerical methylation matrix is calculated using a classification algorithm.
[0307] 59. The method according to embodiment 58, wherein the classification algorithm is linear discriminant analysis, logistic regression, naive bayes classification, perceptron classification, quadratic classification, nearest neighbor, boosting, decision tree, random forest, neural network, learning vector quantization, or support vector machine.
[0308] 60. The method according to any one of embodiments 55 to 59, wherein a methylation matrix is compared with a threshold or reference value to assess the methylation status of a sample (e.g., a blood sample).
[0309] 61. The method according to any one of embodiments 52 to 60, wherein the methylation measure of each of the target polynucleotides is obtained using a computer.
[0310] 62. The method according to any one of embodiments 55 to 61, wherein the methylation matrix of a sample (e.g., a blood sample) is obtained using a computer based on the methylation measure from each of the tissue-specific or organ-specific target polynucleotides.
[0311] 63. The method according to any one of embodiments 1 to 62, wherein the methylation status of at least two tissue-specific or organ-specific target polynucleotides from a plurality of samples (e.g., from a plurality of subjects) is evaluated sequentially or simultaneously.
[0312] 64. The method according to any one of embodiments 1 to 63 has a sensitivity of at least 10%.
[0313] 65. The method according to any one of embodiments 5 to 63 is more sensitive for assessing tissue or organ damage or toxicity in a subject than the method for assessing tissue or organ damage or toxicity in a subject by measuring another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity).
[0314] 66. The method according to embodiment 65 has a higher sensitivity for assessing tissue damage or toxicity in a subject than the sensitivity for assessing tissue damage or toxicity in a subject by measuring another biomarker (e.g., the gold standard biomarker for assessing tissue damage or toxicity).
[0315] 67. The method according to embodiment 65 has a higher sensitivity for assessing organ damage or toxicity in subjects than the sensitivity for assessing organ damage or toxicity in subjects by measuring another biomarker (e.g., the gold standard biomarker for assessing organ damage or toxicity).
[0316] 68. The method according to any one of embodiments 1 to 167 has at least 10% specificity.
[0317] 69. The method according to any one of claims 5 to 68, wherein the specificity for assessing tissue or organ damage or toxicity in a subject is higher than that for assessing tissue or organ damage or toxicity in a subject by measuring another biomarker (e.g., the gold standard biomarker for assessing tissue or organ damage or toxicity).
[0318] 70. The method according to embodiment 69 has a higher specificity for assessing tissue damage or toxicity in a subject than the specificity for assessing tissue damage or toxicity in a subject by measuring another biomarker (e.g., the gold standard biomarker for assessing tissue damage or toxicity).
[0319] 71. The method according to embodiment 69 has a higher specificity for assessing organ damage or toxicity in a subject than the specificity for assessing organ damage or toxicity in a subject by measuring another biomarker (e.g., a gold standard biomarker for assessing tissue damage or toxicity).
[0320] 72. The method according to any one of embodiments 5 to 71, used to assess tissue or organ damage or toxicity in a subject at a stage where such damage or toxicity cannot be detected by another assay of another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity).
[0321] 73. The method according to embodiment 72 is used to assess tissue damage or toxicity in a subject at a stage where the subject's tissue damage or toxicity cannot be detected by another assay of another biomarker (e.g., a gold standard biomarker for assessing tissue damage or toxicity).
[0322] 74. The method according to embodiment 72 is used to assess organ damage or toxicity in a subject at a stage where the subject's organ damage or toxicity cannot be detected by another assay of another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity).
[0323] 75. The method according to any one of embodiments 5 to 71, which is used to assess damage or toxicity to multiple tissues and / or multiple organs (e.g., all tissues and / or organs of the subject) in a single test.
[0324] 76. The method according to embodiment 75 is used to assess damage or toxicity to multiple tissues (e.g., all tissues of the subject) in a single test.
[0325] 77. The method according to embodiment 75 is used to assess damage or toxicity to multiple organs (e.g., all organs of the subject) of a subject in a single test.
[0326] 78. The method according to any one of embodiments 5 to 77 further includes assessing the subject’s tissue or organ damage or toxicity by measuring another biomarker (e.g., a gold standard biomarker for assessing tissue or organ damage or toxicity).
[0327] 79. The method according to any one of embodiments 5 to 78, used to assess tissue or organ damage or toxicity in animal subjects in animal testing.
[0328] 80. The method according to embodiment 79, used to assess tissue or organ damage or toxicity over time from a single animal.
[0329] 81. The method according to any one of embodiments 5 to 78, used to evaluate tissue or organ damage or toxicity in human subjects in preclinical or clinical studies.
[0330] 82. The method according to any one of embodiments 5 to 81 is used for the diagnosis, prognosis, stratification, risk assessment or treatment monitoring of tissue or organ damage or toxicity in a subject.
[0331] 83. The method according to any one of embodiments 1 to 82, used to assess liver injury or toxicity in a subject.
[0332] 84. The method according to embodiment 83, wherein the tissue-specific or organ-specific target polynucleotide: a) Located in one or more liver-specific genes listed in Table 1 or 2; or c) includes, consists substantially of, or comprises one or more sequences shown in one or more of SEQ ID NO: 246-730, or sequences that are complementary to or substantially complementary to them.
[0333] 85. The method according to any one of embodiments 1 to 82, used to assess testicular (testicle or testis) damage or toxicity in a subject.
[0334] 86. The method according to embodiment 85, wherein the tissue-specific or organ-specific target polynucleotide: a) Genes located in the group selected from the following: B3galt1, Cacng5, Ccdc162, Cdc23, Cdca2, Ceacam5, Cnot4, Crybg1, Ddr1, Dpysl4, Enc1, Fam69b, Hs6st3, Ins1, Maml2, Midn, Obox5, Pax7, Pdlim4, Rtn4ip1, Siglec15, Slc16a3, Slc22a4, Smim23, Snx33, Syndig1, Tagln, Tcf3, Trpc7 and TTC8 ; b) Located in one or more genes specific to the testicle (testicle or testis) as listed in Tables 1 and 2; or c) includes, consists substantially of, or comprises one or more sequences shown in one or more of SEQ ID NO: 1-245, or sequences that are complementary to or substantially complementary to them.
[0335] 87. A group of isolated polynucleotides comprising, consisting of, or substantially consisting of one or more isolated tissue-specific or organ-specific target polynucleotides, or sequences complementary to or substantially complementary to them.
[0336] 88. The group according to embodiment 87, wherein each of the isolated tissue-specific or organ-specific target polynucleotides: a) Located in one or more liver-specific genes listed in Table 1 or 2; or c) includes, consists substantially of, or comprises one or more sequences shown in one or more of SEQ ID NO: 246-730, or sequences that are complementary to or substantially complementary to them.
[0337] 89. The group according to embodiment 87, wherein each of the isolated tissue-specific or organ-specific target polynucleotides: a) Genes located in the group selected from the following: B3galt1, Cacng5, Ccdc162, Cdc23, Cdca2, Ceacam5, Cnot4, Crybg1, Ddr1, Dpysl4, Enc1, Fam69b, Hs6st3, Ins1, Maml2, Midn, Obox5, Pax7, Pdlim4, Rtn4ip1, Siglec15, Slc16a3, Slc22a4, Smim23, Snx33, Syndig1, Tagln, Tcf3, Trpc7 and TTC8 ; b) Located in one or more testis-specific genes as listed in Table 1 or 2; or c) includes, consists substantially of, or comprises one or more sequences shown in one or more of SEQ ID NO: 1-245, or sequences that are complementary to or substantially complementary to them.
[0338] 90. The group according to any one of embodiments 87 to 89, comprising, consisting of, or substantially consisting of: at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, or more isolated tissue-specific or organ-specific target polynucleotides, such as isolated tissue-specific or organ-specific target polynucleotides of the subject’s whole genome, or sequences complementary to or substantially complementary to them.
[0339] 91. The group according to any one of embodiments 87 to 90, wherein the isolated tissue-specific or organ-specific target polynucleotide is a DNA molecule, an RNA molecule, or a combination thereof.
[0340] 92. The group according to any one of embodiments 87 to 91, wherein the isolated polynucleotide is immobilized on a substrate.
[0341] 93. The group according to embodiment 92, wherein the substrate includes a solid surface, a porous surface, or a combination thereof.
[0342] 94. The group according to embodiment 92 or 93, wherein the substrate is part of a bead, tube, microtiter plate, membrane, gel or glass slide.
[0343] 95. The group according to any one of embodiments 92 to 94, wherein the separated polynucleotide molecules are spatially separated from each other on the substrate.
[0344] 96. A kit or system comprising the group according to any one of claims 87 to 95.
[0345] 97. The kit or system of claim 96, configured to assess the methylation status of one or more tissue-specific or organ-specific target polynucleotides or sequences complementary or substantially complementary thereto, for example, configured to assess in vitro the methylation status of the one or more tissue-specific or organ-specific target polynucleotides or sequences complementary or substantially complementary thereto in one or more samples, the one or more samples comprising cell-free target polynucleotides from a subject.
[0346] 98. The kit or system according to embodiment 97, configured to evaluate the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000 or more isolated tissue-specific or organ-specific target polynucleotides (e.g., isolated tissue-specific or organ-specific target polynucleotides of the subject’s whole genome, or sequences complementary or substantially complementary to them).
[0347] 99. The kit or system according to any one of embodiments 96 to 98, wherein the isolated polynucleotide is configured as a control polynucleotide.
[0348] 100. The kit or system according to embodiment 99, wherein the isolated polynucleotide has a concentration level of about 1 femtomolar to about 1 millimole.
[0349] 101. A kit or system comprising reagents for assessing the methylation status of one or more tissue-specific or organ-specific target polynucleotides or sequences complementary to or substantially complementary to them.
[0350] 102. The kit or system according to embodiment 101, comprising reagents for evaluating the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides (e.g., isolated tissue-specific or organ-specific target polynucleotides from the whole genome of a subject, or sequences complementary to or substantially complementary to them).
[0351] 103. The kit or system according to embodiment 101 or 102, wherein the reagent comprises, consists substantially of, or is composed of probes or primers, said probes or primers being configured to hybridize with each of the tissue-specific or organ-specific target polynucleotides whose methylation status is to be evaluated.
[0352] 104. The kit or system according to embodiment 103, wherein the reagent comprises a single probe or primer, consists substantially of a single probe or primer, or consists of a single probe or primer configured to hybridize with each of the tissue-specific or organ-specific target polynucleotides whose methylation status is to be evaluated.
[0353] 105. The kit or system according to embodiment 103, wherein the reagent comprises, is substantially composed of, or is composed of a plurality of probes or primers, the plurality of probes or primers being configured to hybridize with each of the tissue-specific or organ-specific target polynucleotides whose methylation status is to be evaluated.
[0354] 106. The kit or system according to any one of embodiments 101 to 105, wherein the one or more primers comprise, consist substantially of, or consist of the sequence shown in any one of SEQ ID NO: 1-SEQ ID NO: 730, a sequence complementary to or substantially complementary to it, or any combination thereof.
[0355] 107. The kit or system according to any one of embodiments 101 to 106, further comprising a common primer for amplifying each target whose methylation state is to be evaluated.
[0356] 108. The kit or system according to embodiment 107, wherein the common primer comprises, is substantially composed of, or is composed of the sequence shown in SEQ ID NO: 731 (CACTCTTTCCCTACACGACGC) or a sequence complementary to or substantially complementary to it.
[0357] 109. The kit or system according to any one of embodiments 101 to 108 further comprises an agent for isolating tissue-specific or organ-specific target polynucleotides from a sample (e.g., a blood or plasma sample) containing cell-free target polynucleotides from a subject.
[0358] 110. The kit or system according to any one of embodiments 101 to 109, further comprising reagents for preparing a target library.
[0359] 111. The kit or system according to embodiment 110, wherein the reagents for preparing the target library include enzymes, such as ligases or single-stranded DNA (ssDNA) ligases.
[0360] 112. The kit or system according to embodiment 111, wherein the ssDNA ligase is T4 RNA ligase I, a thermostable 5' App DNA / RNA ligase, T4 RNA ligase 2, a truncated T4 RNA ligase 2, such as a truncated T4 RNA ligase 2, a truncated T4 RNA ligase 2 K227Q, a truncated T4 RNA ligase 2 KQ, or a T4 DNA ligase, a Thermus phage RNA ligase, such as phage TS2126 RNA ligase (e.g., CircLigase™ and CircLigase II™), or an Archaebacterium RNA ligase, such as Methanobacterium thermoautotrophicum RNA ligase 1.
[0361] 113. The kit or system according to any one of embodiments 101 to 112 further includes reagents for amplifying the tissue-specific or organ-specific target polynucleotide or a library of the tissue-specific or organ-specific target polynucleotide.
[0362] 114. The kit or system according to embodiment 113, wherein the reagents for amplifying the target or the target library include enzymes, such as enzymes for polynucleotide amplification reactions, such as polymerase chain reaction (PCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA), ligase chain reaction (LCR), nucleic acid sequence-based amplification (NASBA), primer extension, rolling circle amplification (RCA), self-sustaining sequence replication (3SR), and loop-mediated isothermal amplification (LAMP).
[0363] 115. The kit or system according to any one of embodiments 101 to 114 further includes agents for purifying tissue-specific or organ-specific target polynucleotides, libraries of tissue-specific or organ-specific target polynucleotides, amplified tissue-specific or organ-specific target polynucleotides, or libraries of amplified tissue-specific or organ-specific target polynucleotides.
[0364] 116. The kit or system according to any one of embodiments 101 to 115, further comprising reagents for assessing the methylation status of the tissue-specific or organ-specific target polynucleotide.
[0365] 117. The kit or system according to embodiment 116, wherein the reagent for assessing the methylation status of the tissue-specific or organ-specific target polynucleotide is a reagent for polynucleotide methylation (e.g., DNA methylation), and the detection methods include mass spectrometry, methylation-specific PCR (MSP), bisulfite sequencing, HpaII microfragment enrichment assay by ligation-mediated PCR (HELP assay), Glasl hydrolysis and ligation adaptor-dependent PCR assay (GLAD-PCR assay), restriction marker genomic scanning (RLGS), methylated DNA immunoprecipitation (MeDIP or mDIP), pyrosequencing, molecular fragmentation assay of DNA adenine methyltransferase activity, methyl-sensitive Southern blotting, and high-resolution melting (HRM) analysis.
[0366] 118. The kit or system according to embodiment 116 or 117, wherein the reagent for assessing the methylation status of the tissue-specific or organ-specific target polynucleotide is a chemical agent, such as bisulfite or sodium bisulfite.
[0367] 119. The kit or system according to embodiment 116 or 117, wherein the reagent for assessing the methylation status of the tissue-specific or organ-specific target polynucleotide is a biological reagent, such as a peptide or enzyme.
[0368] 120. The kit or system according to embodiment 119, wherein the enzyme is a methylation-sensitive restriction enzyme (MSRE).
[0369] 121. The kit or system according to embodiment 120, wherein the MSRE selectively cleaves residues when unmethylated.
[0370] 122. The kit or system according to embodiment 120, wherein when methylated, the MSRE selectively cleaves at the residues.
[0371] 123. The kit or system according to any one of embodiments 120 to 122, wherein the MSRE is selected from the group consisting of: HpaII, SalI, SalI-HF®, ScrFI, BbeI, NotI, SmaI, XmaI, MboI, BstBI, ClaI, MluI, NaeI, NarI, PvuI, SacII, HhaI, and combinations thereof.
[0372] 124. The kit or system according to embodiment 119, wherein the enzyme is a polynucleotide polymerase.
[0373] 125. The kit or system according to embodiment 124, wherein the polynucleotide polymerase is configured for PCR.
[0374] 126. The kit or system according to embodiment 125, wherein the polynucleotide polymerase is a DNA polymerase, such as a DNA polymerase without 3' to 5' exonuclease activity.
[0375] 127. The kit or system according to any one of embodiments 101 to 126, further comprising the group according to any one of claims 87 to 95.
[0376] 128. The kit or system according to any one of embodiments 101 to 127 further includes information on a reference sample and / or a control locus.
[0377] 129. The kit or system according to any one of embodiments 101 to 128 further includes separate containers for one or more components, such as vials, and / or instructions for use of the kit or system.
[0378] 130. The kit or system according to any one of embodiments 101 to 128 further includes a computer-readable medium containing executable instructions for obtaining a methylation measure of a sample (e.g., a blood or plasma sample) based on methylation status assessment.
[0379] 131. The kit or system according to embodiment 130, wherein the computer-readable medium is configured to obtain methylation metrics in the form of average methylation frequency, methylated haplotype load, unmethylated haplotype load, percentage of inconsistent reads, or a combination thereof.
[0380] 132. The kit or system according to any one of embodiments 101 to 128, configured to evaluate a classification sample, or configured to evaluate tissue damage or toxicity in a subject.
[0381] 133. The method according to any one of embodiments 1 to 86, wherein the one or more tissue-specific or organ-specific target polynucleotides comprise, consist of, or substantially consist of at least four consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, the tissue-specific or organ-specific target gene encoding RNA or polypeptide specific to the tissue or organ of the subject.
[0382] 134. The method according to embodiment 133, wherein the tissue-specific or organ-specific target gene is selectively or primarily expressed and / or translated in multiple tissues or organs of the subject.
[0383] 135. The method according to embodiment 133, wherein the tissue-specific or organ-specific target gene is expressed and / or translated only in a single tissue or organ of the subject.
[0384] 136. The group, kit, or system according to any one of embodiments 87 to 132, wherein the one or more tissue-specific or organ-specific target polynucleotides comprise, consist of, or substantially consist of at least four consecutive polynucleotides of a tissue-specific or organ-specific target gene of the subject, the tissue-specific or organ-specific target gene encoding RNA or polypeptide specific to the tissue or organ of the subject.
[0385] 137. The group, kit, or system according to embodiment 136, wherein the tissue-specific or organ-specific target gene is selectively or primarily expressed and / or translated in multiple tissues or organs of the subject.
[0386] 138. The kit, reagent kit, or system according to embodiment 136, wherein the tissue-specific or organ-specific target gene is expressed and / or translated only in a single tissue or organ of the subject.
[0387] G. Example 1. Example 1. Detection of drug-induced liver injury in rats summary Background Technology Cell-free DNA has been used as a biomarker for cancer detection and prenatal testing. Numerous methods have been reported for identifying tissue of origin based on DNA methylation information primarily carried by cell-free DNA. This study aimed to verify whether such methods for detecting DNA released into the bloodstream due to cell death (such as necrosis and apoptosis) could also be used to detect tissue damage caused by the administration of toxic compounds.
[0388] result Male Sprague Dawley rats were used in this study. Organs were derived from normal organs (liver, kidney (medulla and cortex separated), heart, stomach, lung, testis, small intestine, colon, and gastrocnemius muscle). A methylation database was created, and 485 liver-specific DNA methylation regions were identified (listed in Table 2). Blood was collected from rats treated with a single oral dose of 45 mg / kg thioacetamide (a typical hepatotoxicant), and plasma cell-free DNA was analyzed to detect liver-derived DNA with high sensitivity. The sensitivity was equal to or better than that of the gold standard biomarkers for hepatotoxicity, AST and ALT.
[0389] in conclusion Using animal models, we have successfully detected liver-derived DNA leaked into the bloodstream during hepatotoxicity with high sensitivity. This demonstrates that it is possible to measure DNA with much higher sensitivity than existing biomarkers, which could be an effective method for developing biomarkers for mild tissue and organ damage that has been difficult to detect until now and for which no biomarkers are available.
[0390] Materials and methods Material Thioacetamide (TAA) was purchased from Sigma-Aldrich (Burlington, USA). Methylcellulose was purchased from Sigma-Aldrich (St. Louis, USA). Cell-free DNA BCT tubes were purchased from Streck (Nebraska, USA). Rat blood was provided by Dr. Mathias Leblanc of the Salk Institute of Biological Studies. Rat liver tissue samples used for tissue background analysis were purchased from Zyagen (California, USA).
[0391] Animal experiments Male Sprague-Dowley rats were purchased from Envigo RMS, Inc. (Indianapolis, Indiana). Animals were acclimatized to the test facility for 3 days prior to administration. At the start of administration, animals were approximately 8 weeks old and weighed between 245 g and 262 g. Animals were housed in groups (up to five animals per cage) on racks with solid bottoms and wood shavings bedding. Water was provided freely. Animals had free access to a certified rodent diet #2104 (Envigo RMS, Inc.) unless fasting was required for the research procedure. Environmental controls were maintained to ensure the following room conditions: temperatures ranging from 22°C to 26°C, relative humidity from 30% to 70%, and a 12-hour light / 12-hour dark cycle. Animals were provided with various cage-enrichment devices but not with dietary enrichment. Animals were assigned to the study using a computerized program designed to maintain a balance of body weight relative to the time of grouping. Animals were randomly grouped according to their body weight. Rats were divided into the three groups shown in Table 3.
[0392] Table 3. Animal research design Animals in Group 1 were naïve (untreated). Animals in Group 2 were given a mediator [0.5% methylcellulose in purified water (w / v)] as a negative control, and animals in Group 3 were given TAA [45 mg / kg body weight (BW)], a hepatotoxic compound, administered orally via tube feeding at a volume of 10 mL / kg BW per dose. Dosage was based on the most recently recorded planned body weight. On the day of planned sacrifice, blood samples were collected from all fasted animals via abdominal vein for clinical chemistry. All animals were anesthetized with isoflurane, and blood samples were collected for necropsy. The first 5 animals in Groups 2 and 3 were necropsy approximately 9 hours after administration on Day 1. The remaining animals in Groups 2 and 3 were necropsy approximately 24 hours after administration on Day 2, and animals in Group 1 were also necropsy at the stated time.
[0393] Macroscopic examination was performed on the external features of the cadavers; external body openings; abdominal, thoracic, and cranial cavities; organs; and tissues. In Group 1, liver, kidney, heart, stomach, lung, testis, small intestine, colon, and gastrocnemius muscle were collected from each animal to create a tissue methylation database. These tissues were rapidly frozen in liquid nitrogen and stored at -80°C until analysis. In Groups 2 and 3, liver samples were collected from each animal for histopathological examination. These liver samples were preserved in 10% neutral buffered formalin, embedded in paraffin, sectioned, prepared on slides, and stained with hematoxylin and eosin. Animal experiments were conducted at Covance Laboratories, which was fully accredited by the Association for Assessment and Certification of Laboratory Animal Care (AAALAC). All procedures for animal experiments complied with applicable animal welfare laws and were approved by the local Institutional Animal Care and Use Committee (IACUC).
[0394] Generation of DNA libraries for sequencing See the description in section E of the detailed implementation.
[0395] Calculation of liver methylation score See the description in section E of the detailed implementation.
[0396] Identification of liver-specific and testis-specific DNA methylation patterns Five liver and five testis tissue samples from male Sprague-Dawley rats, along with five bulk healthy plasma samples, were purchased from a commercial supplier (Zyagen). DNA was extracted from all 15 samples using the Qiagen DNEasy Extraction Kit with 25 mg of tissue or 2 mL of plasma. All samples were processed using RRBS, and the resulting sequencing data were processed using the Singlera MONOD+ methylation analysis method (where methylation haplotype measures MHL, uMHL, AMF, and PDR were calculated for each methylation haplotype block). The methylation measures for each sample were combined into a data matrix, with each row corresponding to a methylation haplotype block and each column corresponding to a sample. Blocks showing elevated methylation measures for one tissue type (liver or testis) but decreased methylation measures for the other two sample types (other corresponding tissues and plasma) were considered "liver-specific" or "testis-specific"; this yielded 311 liver-specific methylation blocks and 245 testis-specific methylation blocks. The average methylation values of these liver-specific and testis-specific regions were used as the “liver methylation score” and “testis methylation score” to measure the level of liver-derived or testis-derived DNA present in the sample. result Summarize The methylation metric used in this study was AMF. The classification method used in this study was logistic regression. An experimental cohort was developed to query 485 liver-specific methylation regions listed in Table 2. Male Sprague-Dawley rats were treated with either a mediator or a single oral dose of thioacetamide (a known hepatotoxic agent), and plasma was collected from each rat at 9 hours or 24 hours post-administration. Plasma was processed using methylation assays, and the AMF metric for each target region was calculated to create a data matrix. A logistic regression-based classifier was fitted to the sum of the mean methylation values for all target regions in Python (using the sklearn module). The resulting classifier score was able to successfully detect liver injury in all drug-treated samples, with no false positives in the mediator samples.
[0397] Comparison with existing liver biomarkers (ALT / AST): The presence of ALT and AST in blood samples from each drug-treated or control rat was tested using an enzymatic method in a standard liver assay kit. The levels of the present liver enzymes were compared to and plotted against a calculated methylation score for each plasma sample. Methylation signatures were able to identify liver injury in all cases with elevated ALT or AST, and showed more significant dissociation for cases treated at 9 hours.
[0398] Animal research The animal study design is shown in Table 3. All animals survived until the program was terminated. No significant changes in body weight related to the test product were observed. Clinical chemistry data are summarized in Table 4.
[0399] Table 4. Clinical Chemistry - Percentage Change Relative to Primary and / or Control Compared with Group 1 (primary) and Group 2 (control), glucose, total cholesterol, and triglyceride levels in Group 3 (TAA) decreased approximately 9 hours after administration. Approximately 24 hours after administration, glucose and cholesterol levels in Group 3 were comparable to those in Groups 1 and 2; however, triglyceride levels remained persistently low. Compared with Group 1 (primary) and Group 2 (control), AST, ALT, and ALP increased approximately 9 hours after administration. AST and ALT continued to increase approximately 24 hours after administration, while ALP remained unchanged for 24 hours. Creatine kinase levels increased only approximately 24 hours after administration. Histopathological findings are shown in Table 5.
[0400] Table 5. Incidence and severity of thioacetamide-related microscopic findings in the liver TAA-related findings occurred in the livers of animals administered 45 mg / kg. On day 1 of administration (9 hours post-administration), the findings consisted of mild apoptosis / necrosis of centrilobular hepatocytes, accompanied by mild monocytic inflammation primarily composed of macrophages and lymphocytes, and minimal neutrophilic inflammation centered in the bile ducts. On day 2 of administration (24 hours post-administration), the progression to moderate hepatocyte apoptosis / necrosis and monocytic inflammation was observed, but no neutrophilic inflammation was observed. These microscopic findings are similar to those previously reported in TAA-induced liver injury in rats (15). These results suggest that TAA treatment successfully induced hepatotoxicity.
[0401] Figure 4AThe liver methylation scores calculated and plotted for liver DNA and cell-free DNA in plasma collected from each animal are shown. Liver samples from untreated, cadaver-treated, and TAA-treated rats showed high scores of 30–40, while plasma from untreated animals showed scores close to 0. This indicates that cell-free DNA from untreated animals includes very little liver-derived cell-free DNA. Additionally, values of approximately 30–40 can be considered liver DNA itself or samples containing a large amount of liver DNA. Similarly, the liver methylation scores in plasma from cadaver-treated rats were comparable to those from untreated animals. Values in cadaver-treated rats did not change with blood collection time. Therefore, the liver methylation scores calculated based on DNA methylation status at 311 sites did not change with administration manipulation or sampling time. In the TAA group, methylation scores varied between 20 and 40 at 9 hours and approached 40 at 24 hours after TAA administration. At 9 hours post-administration, blood contained liver-derived DNA, and at 24 hours, blood contained even more liver-derived DNA. Twenty-four hours later, the scores in TAA plasma were almost identical to those in liver tissue, indicating that most of the cell-free DNA in TAA plasma was liver-derived DNA. These results suggest that TAA-induced hepatocellular damage leads to a large amount of hepatocellular-derived DNA in the blood.
[0402] Figure 4B The values of ALT and AST, common hepatotoxicity biomarkers, were compared with the liver methylation score. Both AST and ALT are activity values of enzymes included in the liver and are highly relevant biomarkers released into the bloodstream when cells are damaged. AST and ALT values increased over time after TAA administration. At 9 hours after TAA administration, ALT was approximately 100–200 U / L, and at 24 hours, it was 300–700 U / L. Similarly, at 9 hours after TAA administration, AST was 200–400 U / L, and at 24 hours, it was 800–1500 U / L. The liver methylation score was already high at 9 hours after TAA administration and remained stable at nearly 40 at 24 hours, while AST and ALT values showed significant variation even at 24 hours post-administration.
[0403] There is an upper limit to the liver methylation score because it is an indicator of the similarity to liver DNA, and this clearly distinguishes it from biomarkers such as AST and ALT. Figure 4CThe results of the incorporation simulation are shown. Computational simulations were performed to simulate lower levels of hepatotoxicity. Plasma treated with TAA for 9 hours and untreated plasma were mixed at ratios of 10% and 90%. Even in the 10-fold diluted sample, the liver methylation score remained significantly higher than that of untreated or cadaver-treated rat plasma. Since AST and ALT levels were approximately 200–400 and 100–200, respectively, 9 hours after TAA administration, AST and ALT levels were considered difficult to capture as biomarkers in the 10-fold diluted sample. Therefore, these results indicate that cell-free DNA is highly sensitive in detecting hepatotoxicity, and its sensitivity is comparable to or better than that of existing biomarkers.
[0404] discuss In this study, we demonstrated whether cell-free cellular DNA can be used as a biomarker for tissue damage assessment in toxicity evaluation. We identified characteristic DNA methylation patterns for each organ in normal rats. Using scores calculated based on the identified liver-specific DNA methylation patterns, we found liver-specific patterns detected in the blood of rats treated with TAA (a typical hepatotoxic agent). This indicates that this approach allows for the detection of hepatotoxicity with sensitivity equal to or better than that of conventional biomarkers.
[0405] like Figure 4AAs shown, an increase in cell-free DNA was observed 9 hours post-administration when changes in existing biomarkers were observed. Furthermore, since the values showed high levels after 24 hours, it is considered that the detection of hepatotoxicity under these test conditions has a capability comparable to existing biomarkers. In addition, results from a 10-fold dilution simulation revealed significant differences from the control group, even at levels undetectable by AST / ALT. This indicates that the cell-free DNA analysis using methylation patterns at 311 sites in rat liver, as discovered in this study, far surpasses the detection capabilities of existing biomarkers. Similarly, it has been reported that overdose of acetaminophen can detect liver injury in mouse models and clinical settings. In a study by Laurent et al. (BMC Medical Genomics, 2020, 13:60; https: / / doi.org / 10.1186 / s12920-020-0705-2), the methylation status of the PTK2B gene (chr8: 27, 183, 116-27, 183, 176, hg19) was used as a biomarker for cell-free DNA in clinical samples using droplet digital PCR (ddPCR). The concentrations of cell-free DNA specific to all patients with elevated ALT levels were higher than those to healthy volunteers, a result consistent with studies using TAAs as hepatotoxic agents. Despite the use of different cell-free DNA detection methods, the ability to detect liver injury in different models further confirms the potential of cell-free DNA as a biomarker of tissue damage.
[0406] High sensitivity suggests the potential to develop new biomarkers for organs that are considered to lack suitable biomarkers or for organs that have biomarkers but are not considered to have high sensitivity. For example, inhibin B is known to be an existing biomarker for testicular toxicity (5, 6), but because it is a hormone, its diurnal variation is large and insufficient to confirm its effects on the testes (16). MicroRNAs have also been reported as testicular biomarkers, but it is unclear whether they have sufficient performance (17). The blood-testis barrier is a barrier that makes it difficult to detect testicular toxicity in the blood, but the high-sensitivity cell-free DNA analysis demonstrated in this study may have the potential to detect even very small amounts of DNA. Furthermore, the method used in this study is based on scoring calculations from comprehensive DNA methylation analysis, while developing targeted sequencing methods for necessary regions holds promise for building a highly sensitive and efficient measurement system. In addition, it is possible to test all organ damage simultaneously on the same platform. If sensitivity can be increased and the amount of blood drawn can be reduced, it may also be possible to examine the toxicological changes of individual animals over time. These possibilities hold promise for addressing many challenges in PCR-based cell-free DNA detection.
[0407] Even in terms of specificity, cell-free DNA is considered superior to existing biomarkers. Although AST and ALT are abundant in hepatocytes, they are also expressed in other organs, so in some cases, high levels of these biomarkers do not necessarily indicate hepatotoxicity (18). For example, AST is expressed not only in the liver but also in the heart, muscle, and kidneys (19), and therefore may show elevated levels when these organs are damaged. In this study, a DNA methylation database of 10 different organs was constructed to identify liver-specific methylation sites and used as biomarkers. Therefore, the liver methylation score developed in this study is calculated based on a methylation pattern that differs from that of other organs, which may make it less sensitive to organ toxicity outside the liver.
[0408] However, challenges also exist. If the administration of some compounds leads to toxicity, the treatment itself may alter the DNA methylation pattern of the organ. Additionally, the effects of animal age or reduced food intake induced by drug toxicology cannot be confirmed. In this study, liver samples showed slightly lower liver methylation scores 24 hours after TAA administration. This could indicate a reduced amount of DNA released from damaged hepatocytes, but it is also possible that the DNA methylation pattern was slightly altered. In other words, such a variety of fundamental data are needed to identify robust regions that are difficult to alter by various factors for selection as biomarkers. On the other hand, because the method uses multiple locations across the entire genome as markers, slight changes in methylation patterns at some locations may not significantly affect their detectability as biomarkers. Furthermore, since cell-free DNA in the blood is rapidly removed after release (20), a suitable detection time may need to be found compared to biomarkers that can remain in the blood for a period of time. Although cell-free DNA may show trends similar to those of liver enzymes such as AST and ALT, fundamental data are needed to elucidate trends in cell-free DNA concentrations in the blood. Although useful DNA characteristic methylation patterns can be obtained in each organ, toxicity may be difficult to detect in some organs. For example, the brain has a blood-brain barrier, which limits the outflow of biomarkers targeted by liquid biopsy; Meng et al. reported that transcranial MR-guided focused ultrasound (MRgFUS (21)) was able to overcome this barrier. Since the testes also have a blood-testis barrier, detecting pathological changes occurring in the seminiferous tubules may require some originality. Higher sensitivity could also overcome these difficulties, but further research is needed. (21) Although it may be more sensitive than AST / ALT, cfDNA may be better used in combination with existing biomarkers. For example, cfDNA can be used to detect early and / or less severe histopathological changes that do not differ significantly between 9 and 24 hours, while AST / ALT can be used to estimate the severity of late and / or more severe histopathological changes. (22 Therefore, cell-free DNA biomarkers are considered to have fully demonstrated their performance when used in combination with currently available biomarkers.
[0409] In summary, this study demonstrates that, in hepatotoxicity models using typical hepatotoxicants, indexing cell-free DNA in the blood via liver-specific methylation patterns performs as well as, or better than, existing biomarkers for liver injury. Because this approach can be applied to various organs, it is theoretically possible to detect damage in all organs using cell-free DNA. Further research could reshape toxicity assessment in drug development.
[0410] Example 2. Detection of drug-induced testicular injury in rats The methylation metric used in this study was AMF. The classification method used in this study was logistic regression. An experimental group was developed to analyze the 245 testis-specific methylation regions listed in Table 2. Male Sprague-Dowley rats were treated with a methylating agent or a single oral dose of ethylene glycol monomethyl ether (a compound known to induce testicular cell toxicity), and plasma was collected from each rat 5 or 10 days after administration. Plasma was processed using methylation assays, and the AMF metric for each target region was calculated to create a data matrix. A logistic regression-based classifier was fitted to the sum of the mean methylation values for all target regions in Python (using the sklearn module). The resulting classifier scores were able to successfully detect testicular damage in all drug-treated samples, showing both dose-dependent and time-dependent effects of drug exposure. The results were also matched with the results of pathological examination of the testes. (See [link to relevant documentation]) Figure 5 and 8 。 Example 3. Generation of a rat tissue-specific methylation database The methylation metric used in this study was AMF. The classification method used in this study was K-means clustering. Commercially available tissue samples were obtained from 10 different organs of male Sprague-Dawley rats: colon, gastrocnemius muscle, heart, kidney, liver, lung, small intestine, stomach, and testis. The methylation status of gene promoter regions in these tissue samples was analyzed using reduced representative bisulfite sequencing (RRBS) with MspI enzyme, and the AMF metric for each target region was calculated to create a data matrix. Based on the distance of AMF values between each sample in Python (using the sklearn module), the samples were classified into 10 groups using a K-means clustering classifier. The resulting classifier was able to accurately classify each tissue into its own category based on tissue-specific or organ-specific methylation patterns, with only one colon (large intestine) sample being misclassified as a small intestine sample. (See also...) Figure 6 and 9 。 List of references: 1. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z et al., Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United States of America (Proc Natl AcadSci US A.) 2009;106(11):4402-7.
[0411] 2. Meunier L, Larrey D. Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation. Front Pharmacol. 2019;10:1482.
[0412] 3. Griffin BR, Faubel S, Edelstein CL. Biomarkers of Drug-Induced Kidney Toxicity. Ther DrugMonit. 2019;41(2):213-26.
[0413] 4. Shah KS, Yang EH, Maisel AS, Fonarow GC. The Role of Biomarkers in Detection of Cardio-toxicity. Current Oncology Reports 2017;19(6):42.
[0414] 5. Stewart J, Turner KJ. Inhibin B as a potential biomarker of testicular toxicity. Cancer Biomarker 2005;1(1):75-91.
[0415] 6. Sasaki JC, Chapin RE, Hall DG, Breslin W, Moffit J, Saldutti L et al., Incidence and nature of testicular toxicity findings in pharmaceutical development. Birth Defects Research B: Dev Reprod Toxicol. 2011;92(6):511-25.
[0416] 7. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C et al., Liquid biopsies come of age: towards implementation of circulating tumor DNA. Nature Reviews Cancer 2017;17(4):223-38.
[0417] 8. Bronkhorst AJ, Wentzel JF, Aucamp J, van Dyk E, du Plessis L, Pretorius PJ. Characterization of the cell-free DNA released by cultured cancer cells. Acta Biochim Biophysica Sinica 2016;1863(1):157-65.
[0418] 9. Breitbach S, Sterzing B, Magallanes C, Tug S, Simon P. Direct measurement of cell-free DNA from serially collected capillary plasma during incremental exercise. Journal of Applied Physiology (1985). 2014;117(2):119-30.
[0419] 10. Rodrigues Filho EM, Simon D, Ikuta N, Klovan C, Dannebrock FA, Oliveira de Oliveira C et al., Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury. J Neurotrauma. 2014;31(19):1639-46.
[0420] 11. De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H et al., Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6(241):241ra77.
[0421] 12. Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. Journal of Clinical Research (J Clin Invest.) 2022;132(12).
[0422] 13. Breveglieri G, D'Aversa E, Finotti A, Borgatti M. Non-invasive Prenatal Testing Using Fetal DNA. Molecular Diagnosis and Therapy 2019;23(2):291-9.
[0423] 14. Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K, Zhang K. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nature Genetics 2017;49(4):635-42.
[0424] 15. Mangipudy RS, Chanda S, Mehendale HM. Tissue repair response as a function of dose inthioacetamide hepatotoxicity. Environ Health Perspect. 1995;103(3):260-7.
[0425] 16. Moffit JS, Her LS, Mineo AM, Knight BL, Phillips JA, Thibodeau MS. Assessment of inhibin B as a biomarker of testicular injury following administration of carbendazim, cetrorelix, or 1,2-dibromo-3-chloropropane in Wistar han rats. Birth Defects Research Part B: Developmental and Reproductive Toxicology 2013;98(1):17-28.
[0426] 17. Shing JC, Schaefer K, Grosskurth SE, Vo AH, Sharapova T, Bodie K et al., Small RNA Sequencing to Discover Circulating MicroRNA Biomarkers of Testicular Toxicity in Dogs. International Journal of Toxicology (Int J Toxicol.) 2021;40(1):26-39.
[0427] 18. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005;41(2):380-2.
[0428] 19. Kobayashi A, Suzuki Y, Sugai S. Specificity of transaminase activities in the prediction of drug-induced hepatotoxicity. Journal of Toxicology Science, 2020;45(9):515-37.
[0429] 20. Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biology and Therapy 2019;20(8):1057-67.
[0430] 21. Meng Y, Pople CB, Suppiah S, Llinas M, Huang Y, Sahgal A et al., MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. NeuroOncol. 2021;23(10):1789-97.
[0431] 22. Khattab, H., Fouad, A., Hamza, M., Mohey, MA, El-Akel, W., Ghoneim, H., Abul-Fotouh, A., & Esmat, G. (2015). Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4. Arab Journal of Gastroenterology: Official Publication of the Pan-Arab Association of Gastroenterology, 16(2), 50-53.
Claims
1. An in vitro method for classifying samples, the method comprising: a) Assess in vitro the methylation status of one or more tissue-specific or organ-specific target polynucleotides of a subject in a sample containing cellular free target polynucleotides from the subject; as well as b) To classify the sample into a category based on the methylation status of one or more tissue-specific or organ-specific target polynucleotides in the sample obtained in a).
2. The method of claim 1, wherein step 1) comprises in vitro assessment of the methylation status of a tissue-specific or organ-specific target polynucleotide of a subject in a sample, said sample comprising cellular free target polynucleotides from said subject.
3. The method of claim 1, wherein step 1) comprises in vitro assessment of the methylation status of two or more tissue-specific or organ-specific target polynucleotides of the subject in a sample, the sample comprising cellular free target polynucleotides from the subject.
4. The method according to any one of claims 1 to 3, wherein step 1) comprises in vitro assessment of the methylation status of one or more tissue-specific target polynucleotides of a subject in a sample, said sample comprising cellular free target polynucleotides from said subject.
5. The method of claim 4, used to assess tissue damage or toxicity in the subject.
6. The method of claim 5, wherein the tissue is selected from the group consisting of connective tissue, epithelial tissue, muscle tissue, and nerve tissue.
7. The method according to any one of claims 1 to 3, wherein step 1) comprises in vitro assessment of the methylation status of one or more organ-specific target polynucleotides of a subject in a sample, said sample comprising cellular free target polynucleotides from said subject.
8. The method of claim 7, used to assess organ damage or toxicity in the subject.
9. The method of claim 8, wherein the organ is an organ of a system selected from the group consisting of: the cardiovascular system, such as the lungs, heart, blood, and blood vessels; the digestive system, such as the salivary glands, esophagus, stomach, liver, gallbladder, pancreas, intestine, colon, mesentery, rectum, and anus; the endocrine system, such as endocrine glands, including the hypothalamus, pituitary gland, pineal gland or pineal gland, thyroid gland, parathyroid gland, and adrenal gland (i.e., adrenal gland); the excretory system, such as the kidneys, ureters, bladder, and urethra; the lymphatic system, such as lymph nodes and lymphatic vessels transporting lymph, including the immune system: defending against pathogenic factors with leukocytes, tonsils, adenoids, thymus, and spleen; The exodermal system, such as the skin, hair, and nails of mammals; the muscular system, such as muscles; the nervous system, such as the brain, spinal cord, and nerves; and the reproductive system, such as sex organs, such as the ovaries, fallopian tubes, uterus, vulva, vagina, testes, vas deferens, seminal vesicles, prostate, and penis. The respiratory system, such as the pharynx, larynx, trachea, bronchi, lungs, and diaphragm; And the skeletal system, such as bones, cartilage, ligaments, and tendons.
10. The method of claim 8, wherein the organ is selected from the group consisting of: liver, kidney, heart, stomach, lung, testis, small intestine, colon, and gastrocnemius muscle.
11. The method according to any one of claims 5 to 10, wherein the tissue or organ damage or toxicity of the subject is due to treatment of the subject with a substance.
12. The method of claim 11, wherein the substance is a drug or a drug candidate.
13. The method according to any one of claims 5 to 12, used to evaluate tissue or organ damage or toxicity in human subjects in preclinical or clinical studies.
14. The method according to any one of claims 5 to 13, used for the diagnosis, prognosis, stratification, risk assessment, or treatment monitoring of tissue or organ damage or toxicity in a subject.
15. The method according to any one of claims 1 to 14, used to assess liver injury or toxicity in a subject.
16. The method of claim 15, wherein the tissue-specific or organ-specific target polynucleotide: a) Located in one or more liver-specific genes listed in Table 1 or 2; or c) Includes, is substantially composed of, or consists of the following: One or more sequences shown in one or more of SEQ ID NO: 246-730, or sequences that are complementary or substantially complementary to them.
17. The method according to any one of claims 1 to 14, used to assess testicular (testicle or testis) damage or toxicity in a subject.
18. The method of claim 17, wherein the tissue-specific or organ-specific target polynucleotide: a) Genes located in the group selected from the following: B3galt1, Cacng5, Ccdc162, Cdc23, Cdca2, Ceacam5, Cnot4, Crybg1, Ddr1, Dpysl4, Enc1, Fam69b, Hs6st3, Ins1, Maml2, Midn, Obox5, Pax7, Pdlim4, Rtn4ip1, Siglec15, Slc16a3, Slc22a4, Smim23, Snx33, Syndig1, Tagln, Tcf3, Trpc7 and Ttc8 ; b) Located in one or more genes that are specific to the testicle (testicle or testis) as listed in Table 1 and 2; or c) includes, consists substantially of, or comprises one or more sequences shown in one or more of SEQ ID NO: 1-245, or sequences that are complementary to or substantially complementary to them.
19. A group of isolated polynucleotides, comprising, consisting of, or substantially consisting of the following: One or more isolated tissue-specific or organ-specific target polynucleotides, or sequences that are complementary or substantially complementary to them.
20. The group according to claim 19, wherein each of the isolated tissue-specific or organ-specific target polynucleotides: a) Located in one or more liver-specific genes listed in Table 1 or 2; or c) Includes, is substantially composed of, or consists of the following: One or more sequences shown in one or more of SEQ ID NO: 246-730, or sequences that are complementary or substantially complementary to them.
21. The group according to claim 19, wherein each of the isolated tissue-specific or organ-specific target polynucleotides: a) Genes located in the group selected from the following: B3galt1, Cacng5, Ccdc162, Cdc23, Cdca2, Ceacam5, Cnot4, Crybg1, Ddr1, Dpysl4, Enc1, Fam69b, Hs6st3, Ins1, Maml2, Midn, Obox5, Pax7, Pdlim4, Rtn4ip1, Siglec15, Slc16a3, Slc22a4, Smim23, Snx33, Syndig1, Tagln, Tcf3, Trpc7 and Ttc8 ; b) Located in one or more genes that are specific to the testicle (testis) as listed in Table 1 or 2; or c) includes, consists substantially of, or comprises one or more sequences shown in one or more of SEQ ID NO: 1-245, or sequences that are complementary to or substantially complementary to them.
22. A kit or system comprising the group according to any one of claims 19 to 21.
23. The kit or system of claim 22, configured to assess the methylation status of one or more tissue-specific or organ-specific target polynucleotides or sequences complementary or substantially complementary thereto, for example, configured to assess in vitro the methylation status of the one or more tissue-specific or organ-specific target polynucleotides or sequences complementary or substantially complementary thereto in one or more samples, the one or more samples comprising cell-free target polynucleotides from a subject.
24. The kit or system of claim 22, configured to evaluate the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000 or more isolated tissue-specific or organ-specific target polynucleotides (e.g., isolated tissue-specific or organ-specific target polynucleotides of the subject’s whole genome, or sequences complementary to or substantially complementary to them).
25. A kit or system comprising reagents for assessing the methylation status of one or more tissue-specific or organ-specific target polynucleotides, or sequences complementary to or substantially complementary to them.
26. The kit or system of claim 25, comprising reagents for evaluating the methylation status of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000 or more tissue-specific or organ-specific target polynucleotides (e.g., isolated tissue-specific or organ-specific target polynucleotides from the whole genome of a subject, or sequences complementary to or substantially complementary to them).
27. The method according to any one of claims 1 to 18, wherein the one or more tissue-specific or organ-specific target polynucleotides comprise, consist of, or are substantially composed of: The subject has at least four consecutive polynucleotides of a tissue-specific or organ-specific target gene, which encodes RNA or polypeptide that is specific to the subject's tissue or organ.
28. The method of claim 27, wherein the tissue-specific or organ-specific target gene is selectively or primarily expressed and / or translated in multiple tissues or organs of the subject.
29. The method of claim 27, wherein the tissue-specific or organ-specific target gene is expressed and / or translated only in a single tissue or organ of the subject.
Citation Information
Patent Citations
Bisulfite conversion of DNA
US20060134643A1
Human genomic polymorphisms
US20060188875A1
Compositions and methods for detection of genomic variance and DNA methylation status
US20200048697A1
Compositions and methods for library construction and sequence analysis
US20200123538A1
Methods for genomic analysis
US6969589B2
